

1. Cloots K, Burza S, Malaviya P, Hasker E, Kansal S, Mollett G, Chakravarty J, Roy N, Lal BK, Rijal S, Sundar S, Boelaert M. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. *PLoS Negl Trop Dis.* 2020 Jan 29;14(1):e0007995. doi: 10.1371/journal.pntd.0007995. eCollection 2020 Jan. PMID: 31995564
  2. De Rycker M, Horn D, Aldridge B, Amewu RK, Barry CE 3rd, Buckner FS, Cook S, Ferguson MAJ, Gobeau N, Herrmann J, Herrling P, Hope W, Keiser J, Lafuente-Monasterio MJ, Leeson PD, Leroy D, Manjunatha UH, McCarthy J, Miles TJ, Mizrahi V, Moshynets O, Niles J, Overington JP, Pottage J, Rao SPS, Read KD, Ribeiro I, Silver LL, Southern J, Spangenberg T, Sundar S, Taylor C, Van Voorhis W, White NJ, Wyllie S, Wyatt PG, Gilbert IH. Setting Our Sights on Infectious Diseases. *ACS Infect Dis.* 2020 Jan 10;6(1):3-13. doi: 10.1021/acsinfecdis.9b00371. Epub 2019 Dec 6. PMID: 31808676
  3. Hasker E, Malaviya P, Scholar VK, de Koning P, Singh OP, Kansal S, Cloots K, Boelaert M, Sundar S. Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site. *PLoS Negl Trop Dis.* 2019 Oct 25;13(10):e0007798. doi: 10.1371/journal.pntd.0007798. eCollection 2019 Oct. PMID: 31652262
  4. Prakash J, Iqbal M, Patel PS, Prakash S, Sundar S, Singh U. Outcome of HIV Related Kidney Diseases Treated with Combined Antiretroviral Therapy (cART). *J Assoc Physicians India.* 2019 Sep;67(9):18-22. PMID: 31561682
  5. Singh B, Bhushan Chauhan S, Kumar R, Singh SS, Ng S, Amante F, de Labastida Rivera F, Singh OP, Rai M, Nylen S, Sundar S, Engwerda C. A molecular signature for CD8+ T cells from visceral leishmaniasis patients. *Parasite Immunol.* 2019 Nov;41(11):e12669. doi: 10.1111/pim.12669. Epub 2019 Sep 30. PMID:31494954
  6. Lappan R, Classon C, Kumar S, Singh OP, de Almeida RV, Chakravarty J, Kumari P, Kansal S, Sundar S, Blackwell JM. Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. *PLoS Negl Trop Dis.* 2019 Sep 6;13(9):e0007444. doi: 10.1371/journal.pntd.0007444. eCollection 2019 Sep. PMID: 31490933
  7. Sundar S, Singh A, Agrawal N, Chakravarty J. Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. *Am J Trop Med Hyg.* 2019 Oct;101(4):795-798. doi: 10.4269/ajtmh.19-0179. PMID: 31436156
  8. Fakiola M, Singh OP, Syn G, Singh T, Singh B, Chakravarty J, Sundar S, Blackwell JM. Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. *PLoS Negl Trop Dis.* 2019 Aug 16;13(8):e0007673. doi: 10.1371/journal.pntd.0007673. eCollection 2019 Aug. PMID: 31419223
  9. Singh OP, Gedda MR, Mudavath SL, Srivastava ON, Sundar S. Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. *Nanomedicine (Lond).* 2019 Jul;14(14):1911-1927. doi: 10.2217/nmm.2018-0448. Epub 2019 Jul 17. PMID: 31313971
  10. Sundar S, Agrawal N, Singh B. Exploiting knowledge on pharmacodynamics/pharmacokinetics for accelerated anti-leishmanial drug discovery/development. *Expert Opin Drug Metab Toxicol.* 2019 Jul;15(7):595-612. doi: 10.1080/17425255.2019.1629417. Epub 2019 Jun 17. PMID: 31174439
  11. Veronica J, Chandrasekaran S, Dayakar A, Devender M, Prajapati VK, Sundar
-

- 
- S, Maurya R. Iron superoxide dismutase contributes to miltefosine resistance in *Leishmania donovani*. *FEBS J.* 2019 May 13. doi: 10.1111/febs.14923. PMID: 31087522
12. Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. *Expert Opin Pharmacother.* 2019 May 7:1-15. doi: 10.1080/14656566.2019.1609940. PMID: 31063412
  13. Bremer Hinckel BC, Marlais T, Airs S, Bhattacharyya T, Imamura H, Dujardin JC, El-Safi S, Singh OP, Sundar S, Falconar AK, Andersson B, Litvinov S, Miles MA, Mertens P. Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis. *PLoS Negl Trop Dis.* 2019 May 6;13(5):e0007353. doi: 10.1371/journal.pntd.0007353. eCollection 2019 May. PMID: 31059497
  14. Gautam A, Gedda MR, Rai M, Sundar S, Chakravarty J. Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. *Curr Mol Med.* 2019 Apr 5. doi: 10.2174/1566524019666190405120441. PMID: 30950352
  15. Chakravarty J, Hasker E, Kansal S, Singh OP, Malaviya P, Singh AK, Chourasia A, Singh T, Sudarshan M, Singh AP, Singh B, Singh RP, Ostyn B, Fakiola M, Picado A, Menten J, Blackwell JM, Wilson ME, Sacks D, Boelaert M, Sundar S. Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. *PLoS Negl Trop Dis.* 2019 Mar 27;13(3):e0007216. doi: 10.1371/journal.pntd.0007216. eCollection 2019 Mar. PMID: 30917114
  16. Joshi S, Yadav NK, Rawat K, Kumar V, Ali R, Sahasrabudde AA, Siddiqi MI, Haq W, Sundar S, Dube A. Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of *Leishmania (Leishmania) donovani*. *Front Immunol.* 2019 Feb 28;10:288. doi: 10.3389/fimmu.2019.00288. eCollection 2019. PMID:30873164
  17. Chauhan SB, Faleiro R, Kumar R, Ng S, Singh B, Singh OP, Singh SS, Amante F, Rivera FL, Rai M, Chakravarty J, Sacks D, Nysten S, Sundar S, Engwerda C. IL-2 is an upstream regulator of CD4+ T cells from visceral leishmaniasis patients with therapeutic potential. *J Infect Dis.* 2019 Feb 23. pii: jiz074. doi: 10.1093/infdis/jiz074. [Epub ahead of print] PMID: 30796820
  18. Singh B, Singh OP, Singh N, Singh SS, Sundar S. Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis. *Am J Trop Med Hyg.* 2019 Feb 18. doi: 10.4269/ajtmh.18-0350. PMID: 30793688
  19. Abeijon C, Alves F, Monnerat S, Wasunna M, Mbui J, Viana AG, Bueno LL, Siqueira WF, Carvalho SG, Agrawal N, Fujiwara R, Sundar S, Campos-Neto A. Development of a multiplexed assay for the detection of *Leishmania donovani/Leishmania infantum* protein biomarkers in the urine of patients with visceral leishmaniasis. *J Clin Microbiol.* 2019 Feb 20. pii: JCM.02076-18. doi: 10.1128/JCM.02076-18. PMID: 30787142
  20. Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: the road ahead. *BMJ.* 2019 Jan 22;364:k5224. doi: 10.1136/bmj.k5224. PMID: 30670453
  21. Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Gupta R, Negi NS, Das P, Sundar S, Singh R, Salotra P. Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL).
-

---

PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922. doi: 10.1371/journal.pntd.0006922. PMID: 30439953

22. Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gilleman Q, Thunissen C, Hinckel BCB, Pearson C, Gardner BL, Airs S, de la Roche M, Hayes K, Hafezi H, Falconar AK, Eisa O, Saad A, Khanal B, Bhattarai NR, Rijal S, Boelaert M, El-Safi S, Sundar S, Miles MA. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis. *Front Cell Infect Microbiol.* 2018 Dec 13;8:427. doi: 10.3389/fcimb.2018.00427. eCollection 2018. PMID: 30619774
  23. Gautam A, Chakravarty J, Singh VK, Ghosh A, Chauhan SB, Rai M, Sundar S. Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. *BMC Infect Dis.* 2018 Dec 27;18(1):692. doi: 10.1186/s12879-018-3618-3. PMID: 30587145
  24. Saha G, Khamar BM, Singh OP, Sundar S, Dubey VK. Leishmania donovani evades Caspase 1 dependent host defense mechanism during infection. *Int J Biol Macromol.* 2018 Dec 22. pii: S0141-8130(18)36295-0. doi: 10.1016/j.ijbiomac.2018.12.185. PMID: 30584943
  25. Mollett G, Bremer Hinckel BC, Bhattacharyya T, Marlais T, Singh OP, Mertens P, Falconar AK, El-Safi S, Sundar S, Miles MA. Detection of IgG1 against rK39 improves monitoring of treatment outcome in visceral leishmaniasis. *Clin Infect Dis.* 2018 Dec 12. doi: 10.1093/cid/ciy1062 PMID: 30541022
  26. Bulstra CA, Le Rutte EA, Malaviya P, Hasker EC, Coffeng LE, Picado A, Singh OP, Boelaert MC, de Vlas SJ, Sundar S. Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India. *PLoS Negl Trop Dis.* 2018 Dec 6;12(12):e0006888. doi: 10.1371/journal.pntd.0006888. eCollection 2018 Dec. PMID: 30521529
  27. Singh B, Fakiola M, Sudarshan M, Oommen J, Singh SS, Sundar S, Blackwell JM. HLA-DRB1 expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis. *Immunology.* 2018 Nov 7. doi: 10.1111/imm.13018. PMID:30403401
  28. Singh B, Singh SS, Sundar S. Hcpidin mediated iron homeostasis as immune regulator in visceral leishmaniasis patients. *Parasite Immunol.* 2018 Nov 6:e12601. doi: 10.1111/pim.12601. PMID: 30402883
  29. Hasker E, Malaviya P, Cloots K, Picado A, Singh OP, Kansal S, Boelaert M, Sundar S. Visceral Leishmaniasis in the Muzaffapur Demographic Surveillance Site: A Spatiotemporal Analysis. *Am J Trop Med Hyg.* 2018 Oct 8. doi: 10.4269/ajtmh.18-0448. PMID: 30298812
  30. Sundar S, Singh OP, Chakravarty J. Visceral Leishmaniasis elimination targets in India, strategies for preventing resurgence. *Expert Rev Anti Infect Ther.* 2018 Oct 5. doi: 10.1080/14787210.2018.1532790. PMID: 30289007
  31. Singh N, Sundar S. Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. *PLoS One.* 13(6):e0199817, 2018. PMID:29953494
  32. Singh N, Kumar R, Chauhan SB, Engwerda C, Sundar S. Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis. *J Infect Dis.* 2018 Jul 19. doi: 10.1093/infdis/jiy228. PMID: 30053070
  33. Sundar S, Singh OP. Molecular Diagnosis of Visceral Leishmaniasis. *Mol*
-

---

Diagn Ther. 2018. PMID: 29922885

34. Sundar S, Singh B. Emerging therapeutic targets for treatment of leishmaniasis. *Expert Opin Ther Targets*. 22(6):467-486, 2018. PMID: 29718739
35. Sundar S, Singh B. Understanding Leishmania parasites through proteomics and implications for the clinic. *Expert Rev Proteomics*. 15(5):371-390, 2018. PMID: 29717934
36. Singh T, Fakiola M, Oommen J, Singh AP, Singh AK, Smith N, Chakravarty J, Sundar S, Blackwell JM. Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. *J Immunol*. 15;200(8):2727-2737, 2018 PMID: 29507109
37. Chaubey P, Mishra B, Mudavath SL, Patel RR, Chaurasia S, Sundar S, Suvarna V, Monteiro M. Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani. *Int J Biol Macromol*. 4;111:109-120, 2018. PMID: 29307805
38. Sundar S, Agarwal D. Visceral Leishmaniasis – Optimum Treatment Options in Children. *Pediatr Infect Dis J*. 37(5):492-494, 2017 .PMID: 29280784
39. Tiwary P, Kumar D, Sundar S. Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis. *Am J Trop Med Hyg*. 98(2):492-496, 2017 .PMID: 29280431
40. Sundar S, Singh A. Chemotherapeutics of visceral leishmaniasis: present and future developments. *Parasitology*. 145(4):481-489, 2017. PMID: 29215329
41. Kumar R, Chauhan SB, Ng SS, Sundar S, Engwerda CR. Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. *Front Immunol*. 8;8:1492, 2017. PMID: 29167671
42. Das S, Giri S, Sundar S, Shaha C. Leishmania donovani Tryparedoxin Peroxidases: functional involvement during infection and drug treatment. *Antimicrob Agents Chemother*. 21;62(1). pii: e00806-17, 2017 PMID: 29061756
43. Verma A, Bhandari V, Deep DK, Sundar S, Dujardin JC, Singh R, Salotra P. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani. *Int J Parasitol Drugs Drug Resist*. 10;7(3):370-377, 2017. PMID:29035735
44. Prakash J, Ganiger V, Prakash S, Sivasankar M, Sundar S, Singh U. Kidney Disease in Human Immunodeficiency Virus-seropositive Patients: Absence of Human Immunodeficiency Virus-associated Nephropathy was a Characteristic Feature. *Indian J Nephrol*. 2017; 27:271-276. doi: 10.4103/0971-4065.202400. PMID: 28761228
45. Sukla S, Roy S, Sundar S, Biswas S. Leptomonas seymouri narna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India. *Arch Virol*. 162(12):3827-3835 , 2017. PMID:28939968
46. Sharma S, Srivastva S, Davis RE, Singh SS, Kumar R, Nysten S, Wilson ME, Sundar S. The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis. *Am J Trop Med* 97(3):767-770, 2017. PMID: 28820688
47. Tandon R, Chandra S, Baharia RK, Misra P, DAS S, Rawat K, Siddiqi MI, Sundar S, Dube A. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate. *Parasitology*. 145(4):508-526, 2017. PMID: 28691653
48. Chakraborty A, Kurati SP, Mahata SK, Sundar S, Roy S, Sen M. Wnt5a Signaling Promotes Host Defense against Leishmania donovani Infection. *J Immunol*. 199(3):992- 1002, 2017. PMID: 28659356

- 
49. Kansal S, Chakravarty J, Kumar A, Malaviya P, Boelaert M, Hasker E, Ostyn B, Sundar S. Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India. *Trop Med Int Health*. 22(8):1037- 1042, 2017. PMID: 28594453
  50. Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, Sundar S, Ramesh V, Dujardin JC, Salotra P. Increased miltefosine tolerance in clinical isolates of *Leishmania donovani* is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. *PLoS Negl Trop Dis*. 11(6):e0005641 ,2017. PMID: 28575060
  51. Chandrasekaran S, Veronica J, Sundar S, Maurya R. Alcoholic Fractions F5 and F6 from *Withania somnifera* Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis. *Front Med (Lausanne)*. 12; 4:55, 2017. PMID: 28553635
  52. Tiwary P, Singh SK, Kushwaha AK, Rowton E, Sacks D, Singh OP, Sundar S, Lawyer P. Establishing, Expanding, and Certifying a Closed Colony of *Phlebotomus argentipes* (Diptera: Phlebotomidae) for Xenodiagnostic Studies at the Kala Azar Medical Research Center, Muzaffarpur, Bihar, India. *J Med Entomol*. 54(5):1129-1139, 2017. PMID: 28525618
  53. Chowdhury SR, Kumar A, Godinho JLP, De Macedo Silva ST, Zuma AA, Saha S, Kumari N, Rodrigues JCF, Sundar S, Dujardin JC, Roy S, De Souza W, Mukhopadhyay S, Majumder HK. Voacamine alters *Leishmania* ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB. *Biochem Pharmacol*. 138:19-30, 2017. PMID:28483460
  54. Lahiry S, Khanra S, Kumar R, Chakraborty A, Sundar S, Sudarshan M, Manna M. Particle induced X-ray emission study of blood samples of Indian Kala-azar patients. *J Parasit Dis*. 41(1):193-198, 2017. PMID: 28316411
  55. Singh N, Sundar S. Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. *Exp Parasitol*. 176:30-45, 2017. PMID:28263760
  56. Singh N, Sundar S. Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells. *Mol Immunol*. 85:111-119 ,2017. PMID:28222329
  57. Olliaro PL, Shamsuzzaman TA, Marasini B, Dhariwal AC, Be-Nazir A, Mondal D, Banjara MR, Das P, Sundar S, Rijal S, Arana B, Alvar J, Argaw D, Peeling RW, Kroeger A, Matlashewski G. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of *Leishmania* in the Indian Subcontinent. *PLoS Negl Trop Dis*. 11(1):e0005190, 2017. PMID: 28125596.
  58. Davis RE, Sharma S, Conceicao J, Carneiro P, Novais F, Scott P, Sundar S, Bacellar O, Carvalho EM, Wilson ME. Phenotypic and functional characteristics of HLA-DR+ neutrophils in Brazilians with cutaneous leishmaniasis. *J Leukoc Biol*. 101(3):739-749, 2016 PMID 28076241
  59. Pandey RK, Mehrotra S, Sharma S, Gudde RS, Sundar S, Shaha C. *Leishmania donovani*- Induced Increase in Macrophage Bcl-2 Favors Parasite Survival. *Front Immunol*. 7:456, 2016. PMID: 27826299
  60. Sharma S, Davis RE, Srivastva S, Nylén S, Sundar S, Wilson ME. A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis. *J Infect Dis*. 214(10):1531-1538, 2016. PMID: 27601622
  61. Chauhan IS, Shukla R, Krishna S, Sekhri S, Kaushik U, Baby S, Pal C,
-

- 
- Siddiqi MI, Sundar S, Singh N. Recombinant *Leishmania* Rab6 (rLdRab6) is recognized by sera from visceral leishmaniasis patients. *Exp Parasitol.* 170:135-147, 2016 .PMID: 27666959
62. Pandey RK, Verma P, Sharma D, Bhatt TK, Sundar S, Prajapati VK. High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. *Biomed Pharmacother.*141-152, 2016. PMID: 27470561
63. Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. *Lancet Infect Dis.* 16(12):e304-e309, 2016. PMID: 27692643
64. Ravinetto R, Becker SL, Sacko M, El-Safi S, Mahendradhata Y, Lutumba P, Rijal S, Lim K, Sundar S, N'Goran EK, Verdonck K, Utzinger J, Chappuis F, Boelaert M. Governance and Standards in International Clinical Research: The Role of Transnational Consortia. *Am J Bioeth.* 16(10):59-61, 2016. PMID: 27653405
65. Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. *Ther Adv Infect Dis.* 3(3-4):98-109, 2016. PMID: 27536354
66. Abeijon C, Singh OP, Chakravarty J, Sundar S, Campos-Neto A. Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. *Am J Trop Med Hyg.* pii: 16-0291,2016. PMID: 27481058
67. Chakravarty J, Kansal S, Tiwary N, Sundar S. Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. *Indian J Community Med.* 41(3):241-4, 2016. PMID: 27385880
68. Singh N, Kumar R, Engwerda C, Sacks D, Nysten S, Sundar S. Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN- $\gamma$  production by spleen cells from human visceral leishmaniasis patients. *Cytokine.* 85:184-90, 2016.PMID: 27372917
69. Pandey RK, Kumbhar BV, Sundar S, Kunwar A, Prajapati VK. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against *Leishmania donovani* trypanothione reductase. *J Recept Signal Transduct Res.* 1-11, 2016. PMID: 27147242
70. Joshi S, Yadav NK, Rawat K, Tripathi CD, Jaiswal AK, Khare P, Tandon R, Baharia RK, Das S, Gupta R, Kushawaha PK, Sundar S, Sahasrabudde AA, Dube A. Comparative Analysis of Cellular Immune Responses in Treated *Leishmania* Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of *Leishmania donovani*. *Front Microbiol.* 7:312, 2016. PMID: 27047452
71. Imamura H, Downing T, Van den Broeck F, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaershot M, Berg M, De Muylder G, Dumetz F, Cuypers B, Maes I, Domagalska M, Decuypere S, Rai K, Uranw S, Bhattarai NR, Khanal B, Prajapati VK, Sharma S, Stark O, Schonian G, De Koning HP, Settimo L, Vanhollebeke B, Roy S, Ostyn B, Boelaert M, Maes L, Berriman M, Dujardin JC, Cotton JA. Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. *Elife.* 5. pii: e12613, 2016. PMID: 27003289
72. Chakravarty J, Chourasia A, Thakur M, Singh AK, Sundar S, Agrawal NR. Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. *Indian J Med Res.* 143(1):79-86, 2016.
-

PMID: 26997018

73. Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. *Infect Dis Poverty*. 5(1):19, 2016. PMID: 26951132
74. Pandey RK, Sundar S, Prajapati VK. Differential Expression of miRNA Regulates T Cell Differentiation and Plasticity During Visceral Leishmaniasis Infection. *Front Microbiol*. 7:206, 2016. PMID: 26941729
75. Khare P, Jaiswal AK, Tripathi CD, Sundar S, Dube A. Immunoprotective responses of Th1 stimulatory protein- S-Adenosyl-L-Homocysteine Hydrolase against Experimental visceral Leishmaniasis. *Clin Exp Immunol*. 185(2):165-79, 2016. PMID: 26898994
76. Chakravarty J, Sharma S, Johri A, Chourasia A, Sundar S. Clinical Abacavir Hypersensitivity Reaction among Children in India. *Indian J Pediatr*. 83(8):855-8, 2016 .PMID: 26887762
77. Faleiro RJ, Kumar R, Bunn PT, Singh N, Chauhan SB, Sheel M, Amante FH, Montes de Oca M, Edwards CL, Ng SS, Best SE, Haque A, Beattie L, Hafner LM, Sacks D, Nylen S, Sundar S, Engwerda CR. Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. *PLoS Negl Trop Dis*. 10(2):e0004415, 2016. PMID: 26872334
78. Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Muller W, Cretney E, Nutt SL, Smyth MJ, Haque A, Hill GR, Sundar S, Kallies A, Engwerda CR. : Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. *PLoS Pathog*. 12(2):e1005460 , 2016 . PMID: 26872135
79. Cameron MM, Acosta-Serrano A, Bern C, Boelaert M, den Boer M, Burza S, Chapman LA, Chaskopoulou A, Coleman M, Courtenay O, Croft S, Das P, Dilger E, Foster G, Garlapati R, Haines L, Harris A, Hemingway J, Hollingsworth TD, Jervis S, Medley G, Miles M, Paine M, Picado A, Poche R, Ready P, Rogers M, Rowland M, Sundar S, de Vlas SJ, Weetman D. Understanding the transmission dynamics of *Leishmania donovani* to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. *Parasit Vectors*. 9(1):25, 2016. PMID: 26812963
80. Sudarshan M, Singh T, Singh B, Chakravarty J, Sundar S. Suppression of host PTEN gene expression for *Leishmania donovani* survival in Indian visceral leishmaniasis. *Microbes Infect*. 18(5):369-72, 2016. PMID: 26774334
81. Sundar S. Visceral leishmaniasis. *Trop Parasitol*. 5(2):83-5, 2015. PMID: 26629448
82. Singh OP, Sundar S. Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. *J Parasitol Res*. 239469, 2015. PMID: 26843964
83. Chakravarty J, Sundar S, Chourasia A, Singh PN, Kurle S, Tripathy SP, Chaturbhuj DN, Rai M, Agarwal AK, Mishra RN, Paranjape RS. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infect Dis*. 15:517, 2015. PMID: 26572102
84. Chandrasekaran S, Veronica J, Gundampati RK, Sundar S, Maurya R. Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of *L. donovani*. *J Enzyme Inhib Med Chem*. 31(6):1029-37, 2015. PMID: 26406482
85. Sudarshan M, Singh T, Chakravarty J, Sundar S. A Correlative Study of Splenic Parasite Score and Peripheral Blood Parasite Load Estimation by

---

Quantitative PCR in Visceral Leishmaniasis. *J Clin Microbiol.* 53(12):3905-7, 2015. PMID: 26400788

86. Kumar Pandey R, Sharma D, Kumar Bhatt T, Sundar S, Kumar Prajapati V. Developing Imidazole analogues as potential inhibitor for *Leishmania donovani* Trypanothione reductase: Virtual Screening, Molecular Docking, Dynamics and ADMET approach. *J Biomol Struct Dyn.* 33(12):2541-53, 2015. PMID: 26305585
87. Kumar Pandey R, Sharma D, Kumar Bhatt T, Sundar S, Kumar Prajapati V. Developing Imidazole analogues as potential inhibitor for *Leishmania donovani* Trypanothione reductase: Virtual Screening, Molecular Docking, Dynamics and ADMET approach. *J Biomol Struct Dyn.* 33(12):2541-53, 2015. PMID: 26305585
88. Mukherjee B, Paul J, Mukherjee S, Mukhopadhyay R, Das S, Naskar K, Sundar S, Dujardin JC, Saha B, Roy S. Antimony-Resistant *Leishmania donovani* Exploits miR-466i To Deactivate Host MyD88 for Regulating IL-10/IL-12 Levels during Early Hours of Infection. *J Immunol.* 195(6):2731-42, 2015. PMID: 26283478
89. Zahraei-Ramazani A, Kumar D, Mirhendi H, Sundar S, Mishra R, Moin-Vaziri V, Soleimani H, Shirzadi MR, Jafari R, Hanafi-Bojd AA, Shahraky SH, Yaghoobi-Ershadi MR. Morphological and Genotypic Variations among the Species of the Subgenus *Adlerius* (Diptera: Psychodidae, Phlebotomus) in Iran. *J Arthropod Borne Dis.* 9(1):84-97, 2015. PMID: 26114146
90. Prakash J, Gupta T, Prakash S, Rathore SS, Usha, Sunder S. Acute kidney injury in patients with human immunodeficiency virus infection. *Indian J Nephrol.* 25(2):86-90, 2015. PMID: 25838645
91. Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Dube A. Correction: Recombinant NAD-dependent SIR-2 Protein of *Leishmania donovani*: Immunobiochemical Characterization as a Potential Vaccine against Visceral Leishmaniasis. *PLoS Negl Trop Dis.* 9(4):e0003742, 2015. PMID: 25901962
92. Picado A, Ostryn B, Rijal S, Sundar S, Singh SP, Chappuis F, Das ML, Khanal B, Gidwani K, Hasker E, Dujardin JC, Vanlerberghe V, Menten J, Coosemans M, Boelaert M. Longlasting insecticidal nets to prevent visceral leishmaniasis in the Indian subcontinent; methodological lessons learned from a cluster randomised controlled trial. *PLoS Negl Trop Dis.* 9(4):e0003597, 2015. PMID: 25856238
93. Kumar A, Samant M, Misra P, Khare P, Sundar S, Dube A. Immunostimulatory potential and proteome profiling of *Leishmania donovani* soluble exogenous antigens. *Parasite Immunol.* 37(7):368-75, 2015. PMID: 25824598
94. Dayakar A, Chandrasekaran S, Veronica J, Sundar S, Maurya R. In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in *Leishmania donovani* infection. *Exp Parasitol.* 153:45-54, 2015. PMID: 25747203
95. Abass E, Kang C, Martinkovic F, Semiao-Santos SJ, Sundar S, Walden P, Piarroux R, El Harith A, Lohoff M, Steinhoff U. Heterogeneity of *Leishmania donovani* Parasites Complicates Diagnosis of Visceral Leishmaniasis: Comparison of Different Serological Tests in Three Endemic Regions. *PLoS One.* 10(3):e0116408, 2015. PMID: 25734336
96. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D,



Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. *PLoS Negl Trop Dis.* 9(3):e0003518. 2015. PMID: 25730310

97. Sundar S, Singh A, Chakravarty J, Rai M. Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis. *Scientific World Journal.* 414378, 2015. PMID: 25685839

98. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Proteomic analyses of membrane enriched proteins of *Leishmania donovani* Indian clinical isolate by mass spectrometry. *Parasitol Int.* 64(4):36-42, 2015. PMID: 25597695

99. Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis. *Expert Opin Investig Drugs.* 24(1):43-59, 2015 PMID: 25409760

100. Sundar S, Singh A, Rai M, Chakravarty J. Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study. *Am J Trop Med Hyg.* 92(3):513-7, 2015. PMID: 25510715

101. Sundar S, Singh A, Rai M, Chakravarty J. Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study. *Am J Trop Med Hyg.* 92(3):513-7, 2015. PMID: 25510715

102. Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. *Parasit Vectors.* 7(1):596, 2014. PMID: 25515494

103. Sudarshan M, Singh T, Singh AK, Chourasia A, Singh B, Wilson ME, Chakravarty J, Sundar S. Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. *PLoS Negl Trop Dis.* 8(12):e3366. , 2014. PMID: 25503103

104. Jaiswal AK, Khare P, Joshi S, Rawat K, Yadav N, Sundar S, Dube A. Immunological consequences of stress-related proteins - cytosolic trypanothione peroxidase and chaperonin TCP20 - identified in splenic amastigotes of *Leishmania donovani* as Th1 stimulatory, in experimental visceral leishmaniasis. *Parasitology.* 142(5):728-44, 2014. PMID: 25498563

105. Chakravarty J, Tiwary NK, Prasad SR, Shukla S, Tiwari A, Mishra RN, Sundar S. Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: A prospective study. *Indian J Med Res.* 140(4):491-500, 2014. PMID: 25488442

106. Kumar D, Tiwary P, Chakravarty J, Sundar S. Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. *Scientific World Journal.* 2014; 2014:852104. PMID: 25405235

107. Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, Gripenberg MA, Bowes DE, Thunissen C, Singh OP, Kumar R, Ahmed O, Eisa O, Saad A, Silva Pereira S, Boelaert M, Mertens P, Miles MA. IgG1 as a Potential Biomarker of Post-chemotherapeutic Relapse in Visceral Leishmaniasis, and Adaptation to a Rapid Diagnostic Test. *PLoS Negl Trop Dis.* 8(10):e3273, 2014. PMID: 25340782

108. Singh S, Sarma S, Katiyar SP, Das M, Bhardwaj R, Sundar D, Dubey

- VK. Probing molecular mechanism of hypericin induced parasitic death: An insight into role of spermidine beyond redox metabolism of *Leishmania*. *Antimicrob Agents Chemother.* 59(1):15-24, 2014. PMID: 25313212
109. Bag AK, Saha S, Sundar S, Saha B, Chakrabarti A, Mandal C. Comparative proteomics and glycoproteomics of plasma proteins in Indian visceral leishmaniasis. *Proteome Sci.* 12(1):48, 2014. PMID: 25276097
110. Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, Rai M, Sacks D, Sundar S, Nylén S. *Leishmania* specific CD4 T cells release IFN $\gamma$  that limits parasite replication in patients with visceral leishmaniasis. *PLoS Negl Trop Dis.* 8(10):e3198, 2014 Oct. PMID: 25275531
111. Jaiswal AK, Khare P, Joshi S, Kushawaha PK, Sundar S, Dube A. Th1 stimulatory proteins of *Leishmania donovani*: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. *PLoS One.* 9(9):e108556, 2014. PMID: 25268700
112. Kumar R, Singh OP, Gautam S, Nylén S, Sundar S. Enhanced expression of Toll Like Receptors (TLRs) 2 & 4, but not 9, in spleen tissue from visceral leishmaniasis patients. *Parasite Immunol.* 36(12):721-5, 2014. PMID: 25244363
113. Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. *PLoS Negl Trop Dis.* 2014 Sep 18;8(9):e3169. PMID: 25233346
114. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Roy S. Imipramine exploits histone deacetylase 11 To Increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant *Leishmania donovani* and clears organ parasites in experimental infection. *J Immunol.* 193(8):4083-94, 2014. PMID: 25217162
115. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Roy S. Imipramine exploits histone deacetylase 11 To Increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant *Leishmania donovani* and clears organ parasites in experimental infection. *J Immunol.* 193(8):4083-94, 2014. PMID: 25217162
116. Malaviya P, Picado A, Hasker E, Ostyn B, Kansal S, Singh RP, Shankar R, Boelaert M, Sundar S. Health & Demographic Surveillance System Profile: The Muzaffarpur-TMRC Health and Demographic Surveillance System. *Int J Epidemiol.* 43(5):1450-7, 2014. PMID: 25186307
117. Malaviya P, Hasker E, Picado A, Mishra M, Van Geertruyden JP, Das ML, Boelaert M, Sundar S. Exposure to *Phlebotomus argentipes* (Diptera, Phlebotomidae, Phlebotominae) sand flies in rural areas of Bihar, India: the role of housing conditions. *PLoS One.* 9(9):e106771, 2014. PMID: 25184542
118. Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. *Front Immunol.* 5:296, 2014. PMID: 25183962
119. Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. *Lancet Glob Health.* 2(1):e51-7,

---

2014. PMID: 25104636

120. Guha R, Das S, Ghosh J, Sundar S, Dujardin JC, Roy S. Antimony resistant *Leishmania donovani* but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF- $\beta$  in early immune response. *PLoS Negl Trop Dis.* 8(7):e2995, 2014. PMID: 25032977
  121. Sudarshan M, Sundar S. Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. *Diagn Microbiol Infect Dis.* 80(1):40-2, 2014. PMID: 25023070
  122. Meena LP, Pandey SK, Rai M, Bharti A, Chakravarty J, Sundar S. Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. *J Educ Health Promot.* 3:31, 2014. PMID: 25013824
  123. Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. *PLoS One.* 9(6):e100220, 2014. PMID: 24941345
  124. Baharia RK, Tandon R, Sahasrabudde AA, Sundar S, Dube A. Nucleosomal histone proteins of *L. donovani*: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against *Leishmania* challenge in hamsters. *PLoS One.* 9(6):e97911, 2014. PMID: 24926878
  125. Sundar S, Singh A, Singh OP. Strategies to overcome antileishmanial drugs unresponsiveness. *J Trop Med.* 646932, 2014. PMID: 24876851
  126. Stauch A, Duerr HP, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Eichner M. Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. *PLoS Negl Trop Dis.* 8(4):e2810. PMID: 24762676
  127. Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S, Dube A. Characterization of the proliferating cell nuclear antigen of *Leishmania donovani* clinical isolates and its association with antimony resistance. *Antimicrob Agents Chemother.* 58(6):2997-3007, 2014. PMID: 24614385
  128. Sundar S, Singh B. Identifying vaccine targets for anti-leishmanial vaccine development. *Expert Rev Vaccines.* 13(4):489-505, 2014. PMID: 24606556
  129. Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dube A, Shrivastav ON, Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. *Adv Exp Med Biol.* 808:77-91, 2014. PMID: 24595612
  130. Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP, Kumar R, Ahmed O, Boelaert M, Miles MA. Significantly Lower Anti-*Leishmania* IgG Responses in Sudanese versus Indian Visceral Leishmaniasis. *PLoS Negl Trop Dis.* 8(2):e2675. PMID: 24587456
  131. Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S. Asymptomatic leishmania infection: A new challenge for leishmania control. *Clin Infect Dis.* 58(10):1424-9, 2014. PMID: 24585564
  132. Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: Challenges and promises. *Immunobiology.* 219(4):323-8, 2014. PMID: 24571797
-

133. Bhandari V, Sundar S, Dujardin JC, Salotra P. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in *Leishmania donovani*. *Antimicrob Agents Chemother.* 58(5):2580-5, 2014. PMID: 24550335
134. Sundar S, Singh A, Tiwari A, Shukla S, Chakravarty J, M. Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. *SRN Parasitol.* 5I48010, 2014. PMID: 27398387
135. Picado A, Ostyn B, Singh SP, Uranw S, Hasker E, Rijal S, Sundar S, Boelaert M, Chappuis F. Risk Factors for Visceral Leishmaniasis and Asymptomatic *Leishmania donovani* Infection in India and Nepal. *PLoS One.* 9(1):e87641, 2014. PMID: 24498159
136. Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabudde AA, Mitra K, Sundar S, Siddiqi MI, Dube A. Characterization of Glycolytic Enzymes - rAldolase and rEnolase of *Leishmania donovani*, Identified as Th1 Stimulatory Proteins, for Their Immunogenicity and Immunoprophylactic Efficacies against Experimental Visceral Leishmaniasis. *PLoS One.* 9(1):e86073, 2014. PMID: 24475071.
137. Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, Kansal S, Singh RP, Singh OP, Chourasia A, Kumar Singh A, Shankar R, Wilson ME, Khanal B, Rijal S, Boelaert M, Sundar S. Strong Association between Serological Status and Probability of Progression to Clinical Visceral Leishmaniasis in Prospective Cohort Studies in India and Nepal. *PLoS Negl Trop Dis.* 8(1):e2657, 2014. PMID: 24466361
138. Goel R, Rai M, Chakravarty J, Meena LP, Tiwary NK, Sundar S, Bharti A. Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study. *J Assoc Physicians India.* 61(4):239-43, 2013. PMID: 24482962
139. Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A. Efficacy of *Leishmania donovani* trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. *Parasitol Res.* 113(3):851-62, 2013. PMID: 24370734
140. Das S, Shah P, Baharia RK, Tandon R, Khare P, Sundar S, Sahasrabudde AA, Siddiqi MI, Dube A. Over-Expression of 60s Ribosomal L23a Is Associated with Cellular Proliferation in SAG Resistant Clinical Isolates of *Leishmania donovani*. *PLoS Negl Trop Dis.* 7(12):e2527, 2013 . PMID: 24340105
141. Van den Bogaart E, Schoone GJ, England P, Faber D, Orrling KM, Dujardin JC, Sundar S, Schallig HD, Adams ER. Simple colorimetric trypanothione reductase-based assay for high-throughput drug screening against *Leishmania* intracellular amastigotes. *Antimicrob Agents Chemother.* 58(1):527-35, 2013. PMID: 24189262.
142. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Mass spectrometry based proteomic analysis of *Leishmania donovani* soluble proteins in Indian clinical isolate. *Pathog Dis.* 70(1):84-7, 2013. PMID: 24115687
143. Rai S, Bhaskar, Goel SK, Nath Dwivedi U, Sundar S, Goyal N. Role of Efflux Pumps and Intracellular Thiols in Natural Antimony Resistant Isolates of *Leishmania donovani*. *PLoS One.* 8(9):e74862, 2013. PMID: 24069359
144. Kumar D, Khanal B, Tiwary P, Mudavath SL, Tiwary NK, Singh R, Koirala K, Boelaert M, Rijal S, Sundar S. Comparative evaluation of blood and serum samples in rapid immunochromatographic tests for visceral

leishmaniasis. *J Clin Microbiol.* 51(12):3955-9, 2013. PMID: 24048530.

145. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S. In vitro susceptibility of *Leishmania donovani* to miltefosine in Indian visceral leishmaniasis. *Am J Trop Med Hyg.* 89(4):750-4, 2013. PMID: 23980130.
146. Hazra S, Ghosh S, Das Sarma M, Sharma S, Das M, Saudagar P, Prajapati VK, Dubey VK, Sundar S, Hazra B. Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of *Leishmania donovani*. *Exp Parasitol.* 135(2):407-13, 2013. PMID: 23973194
147. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, Sundar S, Nylén S. CD8 T Cell Exhaustion in Human Visceral Leishmaniasis. *J Infect Dis.* 209(2):290-9. PMID: 23922369
148. Das M, Saudagar P, Sundar S, Dubey VK. Miltefosine unresponsive *Leishmania donovani* has better ability of resist reactive oxygen species. *FEBS J.* 280(19):4807-15, 2013. PMID: 23890327
149. Naznin E, Kroeger A, Siddiqui NA, Sundar S, Malaviya P, Mondal D, Huda MM, Das P, Karki P, Banjara MR, Dreesch N, Gedik G. Human resource assessment for scaling up VL active case detection in Bangladesh, India and Nepal. *Trop Med Int Health.* 18(6):734-42, 2013. PMID: 23651494
150. Tiwary P, Kumar D, Mishra M, Singh RP, Rai M, Sundar S. Seasonal Variation in the Prevalence of Sand Flies Infected with *Leishmania donovani*. *PLoS One.* 8(4):e61370, 2013. PMID: 23585896
151. Guha R, Das S, Ghosh J, Naskar K, Mandala A, Sundar S, Dujardin JC, Roy S. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of *Leishmania (Leishmania) donovani*. *Vaccine.* 31(15):1905-15, 2013. PMID: 23499564
152. Ostyn B, Malaviya P, Hasker E, Uranw S, Singh RP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project. *Trop Med Int Health.* 18(6):725-33, 2013. PMID: 23464638
153. Srivastava P, Gidwani K, Picado A, Van der Auwera G, Tiwary P, Ostyn B, Dujardin JC, Boelaert M, Sundar S. Molecular and serological markers of *Leishmania donovani* infection in healthy individuals from endemic areas of Bihar, India. *Trop Med Int Health.* 18(5):548-54, 2013. PMID: 23464581
154. Hasker E, Kansal S, Malaviya P, Gidwani K, Picado A, Singh RP, Chourasia A, Singh AK, Shankar R, Menten J, Wilson ME, Boelaert M, Sundar S. Latent infection with *Leishmania donovani* in highly endemic villages in Bihar, India. *PLoS Negl Trop* 7(2):e2053, 2013. PMID: 23459501
155. Singh N, Chikara S, Sundar S. SOLiD™ sequencing of genomes of clinical isolates of *Leishmania donovani* from India confirm leptomonas co-infection and raise some key questions. *PLoS One.* 8(2):e55738, 2013. PMID: 23418454
156. Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in *Leishmania donovani* promastigotes by withanolides. *Parasitol Int.* 62(3):253-61, 2013. PMID: 23416156
157. Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, Allam US, Chakravorty D, Sundar S, Dujardin JC,

- 
- Roy S. Antimony-resistant but not antimony-sensitive *Leishmania donovani* up-regulates host IL-10 to overexpress multidrug-resistant protein 1. *Proc Natl Acad Sci U S A.* 110(7):E575-82, 2013. PMID: 23341611
158. LeishGEN Consortium; Wellcome Trust Case Control Consortium 2, Fakiola M, Strange A, Cordell HJ, Miller EN, Pirinen M, Su Z, Mishra A, Mehrotra S, Monteiro GR, Band G, Bellenguez C, Dronov S, Edkins S, Freeman C, Giannoulatou E, Gray E, Hunt SE, Lacerda HG, Langford C, Pearson R, Pontes NN, Rai M, Singh SP, Smith L, Sousa O, Vukcevic D, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Wilson ME, Deloukas P, Peltonen L, Christiansen F, Witt C, Jeronimo SM, Sundar S, Spencer CC, Blackwell JM, Donnelly P. Common variants in the HLA-DRB1- HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. *Nat Genet.* 45(2):208-13, 2013. PMID: 23291585
159. Malaviya P, Ravinetto R, Sundar S. Ethical research is grounded in quality data: a clinical data management workshop in Varanasi. *Indian J Med Ethics.* 10(2):132, 2013. PMID: 23697499
160. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. *Vaccine.* 31 Suppl 2:B244-9, 2013. PMID: 23598489
161. Sundar S, Singh A. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis? *Expert Rev Anti Infect Ther.* 11(2):117-9, 2013. PMID: 23409817
162. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. *Expert Opin Pharmacother.* 14(1):53-63, 2013. PMID: 23256501
163. Malaviya P, Hasker E, Singh RP, Van Geertruyden JP, Boelaert M, Sundar S. Village health workers in Bihar, India: an untapped resource in the struggle against kala-azar. *Trop Med Int Health.* 18(2):188-93, 2013. PMID: 23279554
164. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of *Leishmania donovani*. *Parasitol Res.* 112(2):825-8, 2013. PMID: 23239091
165. Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. *Trop Med Int Health.* 18(1):96-100, 2013. PMID: 23136856
166. Kumar P, Kumar R, Pandey H, Sundar S, Pai K. Studies on the arginase, 5'-nucleotidase and lysozyme activity by monocytes from visceral leishmaniasis patients. *J Parasit Dis.* 36(1):19-25, 2012. PMID: 23542635
167. Singh OP, Sundar S. Analysis of Total Urine Proteins: Towards A Non-Invasive Approach for Diagnosis of Visceral Leishmaniasis. *J Mol Biomark Diagn.* 3(131), 2012. PMID: 23503981
168. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Das AK, Roy S. Imipramine is an orally active drug against both antimony sensitive and resistant *Leishmania donovani* clinical isolates in experimental infection. *PLoS Negl Trop Dis.* 6(12):e1987, 2012. PMID: 23136856
-

23301108

169. Picado A, Rijal S, Sundar S, Boelaert M. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable. *Expert Rev Anti Infect Ther.* 10(8):839-41, 2012. PMID: 23030320
170. Sundar S, Chakravarty J. Recent advances in the diagnosis and treatment of kala-azar. *Natl Med J India.* 25(2):85-9, 2012. PMID: 22686715
171. Sundar S, Prajapati VK. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. *Curr Med Chem.* 19(19):3196-202, 2012. PMID: 22612703
172. Singh B, Sundar S. Leishmaniasis: Vaccine candidates and perspectives. *Vaccine.* 30(26):3834-42, 2012. PMID: 22475861
173. Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M. Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant *L. donovani* in Bihar, India. *PLoS Negl Trop Dis.* 6(12):e1973, 2012. PMID: 23285309
174. Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M. Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India. *Trop Med Int Health.* 2012 Dec 28. PMID: 23279744
175. Tiwary P, Kumar D, Rai M, Sundar S. PCR-RFLP based method for molecular differentiation of sand fly species *Phlebotomus argentipes*, *Phlebotomus papatasi*, and *Sergentomyia babu* found in India. *J Med Entomol.* 2012; 49:1515-8. PMID: 23270185
176. Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. *PLoS Negl Trop Dis.* 6(10):e1874, 2012. PMID: 23150744.
177. Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, Dube A. *Leishmania donovani* Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis. *PLoS One.* 7(9):e45766, 2012. PMID: 23049855
178. A, Chandrasekaran S, Prajapati VK, Veronica J, Sundar S, Maurya R. A rapid method to assess the stage differentiation in *Leishmania donovani* by flow cytometry. *Exp Parasitol.* 132(4):495-500, 2012. PMID: 23022521
179. Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S. Visceral leishmaniasis in rural Bihar, India. *Emerg Infect Dis.* 18(10):1662-4, 2012. PMID: 23017164
180. Pulimood SA, Rupali P, Ajjampur SS, Thomas M, Mehrotra S, Sundar S. Atypical mucocutaneous involvement with *Leishmania donovani*. *Natl Med J India.* 25(3):148-50, 2012. PMID: 22963292
181. Cunningham J, Hasker E, Das P, El Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M; for the WHO/TDR Visceral Leishmaniasis Laboratory Network. A Global Comparative Evaluation of Commercial Immuno-chromatographic Rapid Diagnostic Tests for Visceral Leishmaniasis. *Clin Infect Dis.* 55(10):1312-9, 2012. PMID: 22942208
182. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S. In vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis— Status of Newly Introduced Drugs. *Am J Trop Med Hyg.* 87(4):655-7, 2012.. PMID: 22927497

- 
183. Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. *Trop Med Int Health*. 17(11):1345-8, 2012. PMID: 22882665
184. Vaish M, Sharma S, Chakravarty J, Sundar S. Evaluation of rKE16 antigen based two novel rapid diagnostic tests for diagnosis of Visceral Leishmaniasis in India. *J Clin Microbiol*. 50(9):3091-2, 2012. PMID: 22760038
185. Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, Roy S, Ostyn B, Maes L, Khanal B, Boelaert M, Schonian G, Berriman M, Chappuis F, Dujardin JC, Sundar S, Rijal S. Genetic markers for SSG-resistance in *Leishmania donovani* and SSG-treatment failure in visceral leishmaniasis patients of the Indian subcontinent. *J Infect Dis*. 206(5):752-5, 2012. PMID: 22753945
186. Hendrickx S, Inocencio da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L. Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of *L. donovani*: Outcome Dependent on In Vitro Selection Protocol. *PLoS Negl Trop Dis*. 6(5):e1664, 2012. PMID: 22666513
187. Olliaro P, Vaillant MT, Sundar S, Balasegaram M. More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. *PLoS Negl Trop Dis*. 6(5):e1545, 2012. PMID: 22666508
188. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P. Drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. *PLoS Negl Trop Dis*. 6(5):e1657, 2012 . PMID: 22629478
189. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis after a Decade of use in India. *Clin Infect Dis*. 55(4):543-50, 2012. PMID: 22573856
190. Mehrotra S, Fakiola M, Mishra A, Sudharshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India. *Infect Genet Evol*. 12(6):1195-201, 2012. PMID: 22561395
191. Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of *Leishmania donovani* Protein Disulfide Isomerase as a Potential Immunogenic Protein/Vaccine Candidate against Visceral Leishmaniasis. *PLoS One*. 7(4):e35670, 2012. PMID: 22539989
192. Singh OP, Gidwani K, Kumar R, Jones SL, Boelaert M, Sacks D, Sundar S. A reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. *Clin Vaccine Immunol*. 19(6):961-6, 2012. PMID: 22539471
193. Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant *Leishmania donovani* p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. *Int J Parasitol*. 42(5):429-35, 2012. PMID: 22502587
194. Kumar S, Kumar D, Chakravarty J, Rai M, Sundar S. Identification and Characterization of a Novel *Leishmania donovani* Antigen for
-



- Serodiagnosis of Visceral Leishmaniasis..Am J Trop Med Hyg. 86(4):601-5, 2012. PMID: 22492143
195. Vaish M, Singh OP, Chakravarty J, Sundar S. rK39 Antigen for the Diagnosis of Visceral Leishmaniasis by Using Human Saliva. Am J Trop Med Hyg. 86(4):598-600, 2012. PMID: 22492142
196. Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B. Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7- dibromocryptolepine against Leishmania donovani promastigotes. *Parasitol Res.* 111(1):195-203. PMID: 22297912
197. Kumari S, Misra P, Tandon R, Samant M, Sundar S, Dube A. Leishmania donovani: Immunostimulatory Cellular Responses of Membrane and Soluble Protein Fractions of Splenic Amastigotes in Cured Patient and Hamsters. *PLoS One.* 7(1):e30746, 2012. PMID: 22292030
198. Tiwary P, Kumar D, Singh RP, Rai M, Sundar S. Prevalence of Sand Flies and Leishmania donovani Infection in a Natural Population of Female Phlebotomus argentipes in Bihar State, India. *Vector Borne Zoonotic Dis.* 12(6):467-72, 2012. PMID: 22217179
199. Prajapati VK, Awasthi K, Yadav TP, Rai M, Srivastava ON, Sundar S. An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes Is an Effective Treatment for Experimental Visceral Leishmaniasis. *J Infect Dis.* 205(2):333-6, 2012. PMID: 22158723
200. Picado A, Singh SP, Vanlerberghe V, Uranw S, Ostyn B, Kaur H, Das ML, Sundar S, Rijal S, Tungu P, Boelaert M, Rowland M. Residual activity and integrity of PermaNet(®) 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. *Trans R Soc Trop Med Hyg.* 106(3):150-9, 2012. PMID: 22137191
201. Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, Decuypere S, de Doncker S, Maes I, Rijal S, Sundar S, Dujardin JC, Berriman M, Schonian G. Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. *Infect Genet Evol.* 12(1):149-59, 2012. PMID: 22119748
202. Ashutosh, Garg M, Sundar S, Duncan R, Nakhasi HL, Goyal N. MAP Kinase1 of Leishmania Donovani: Down Regulation Associates With Antimony Resistance in Field Isolates. *Antimicrob Agents Chemother.* 56(1):518-25, 2012. PMID: 22064540
203. Vaish M, Bhatia A, Reed SG, Chakravarty J, Sundar S. Evaluation of rK28 antigen for serodiagnosis of visceral Leishmaniasis in India. *Clin Microbiol Infect.* 18(1):81-5, 2012. PMID: 21722262
204. Mehrotra S, Fakiola M, Oommen J, Jamieson SE, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India. *BMC Med Genet.* 12(1):162, 2011. PMID: 22171941
205. Samanta S, Dutta D, Ghoshal A, Mukhopadhyay S, Saha B, Sundar S, Jarmalavicius S, Forger M, Mandal C, Walden P, Mandal C. Glycosylation of Erythrocyte Spectrin and Its Modification in Visceral Leishmaniasis. *PLoS One.* 6(12):e28169, 2011. PMID: 22164239
206. Sinha PK, Jha TK, Thakur CP, Nath D, Mukherjee S, Aditya AK, Sundar S. Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the

- Treatment of Visceral Leishmaniasis in India. *J Trop Med.* 645203, 2011. PMID: 22174722
207. Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. *PLoS Negl Trop Dis.* 5(11):e1405, 2011. PMID: 22140589
208. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. Elongation Factor-2, a Th1 Stimulatory Protein of *Leishmania donovani*, Generates Strong IFN- $\gamma$  and IL-12 Response in Cured *Leishmania*-Infected Patients/Hamsters and Protects Hamsters against *Leishmania* Challenge. *J Immunol.* 187(12):6417-27, 2011. PMID: 22079980
209. Weirather JL, Jeronimo SM, Gautam S, Sundar S, Kang M, Kurtz MA, Haque R, Schriefer A, Talhari S, Carvalho EM, Donelson JE, Wilson ME. Serial Quantitative PCR Assay for Detection, Species Discrimination, and Quantification of *Leishmania* spp. in Human Samples. *J Clin Microbiol.* 49(11):3892-904, 2011. PMID: 22042830
210. Downing T, Imamura H, Decuyper S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schonian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. *Genome Res.* 21(12):2143-56, 2011. PMID: 22038251
211. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, Rijal S, Sundar S, Boelaert M. incidence of Symptomatic and Asymptomatic *Leishmania donovani* Infections in High-Endemic Foci in India and Nepal: A Prospective Study. *PLoS Negl Trop Dis.* 5(10):e1284, 2011. PMID: 21991397
212. Kumar N, Singh SP, Mondal D, Joshi A, Das P, Sundar S, Kroeger A, Hirve S, Siddiqui NA, Boelaert M. How do health care providers deal with kala-azar in the Indian subcontinent? *Indian J Med Res.* 134(3):349-55, 2011. PMID: 21985818
213. Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent? *PLoS Negl Trop Dis.* 5(9):e1227, 2011. PMID: 21980542
214. Kumar D, Kumar S, Chakravarty J, Sundar S. A Novel 12.6-kDa Protein of *Leishmania donovani* for the Diagnosis of Indian Visceral Leishmaniasis. *Vector Borne Zoonotic Dis.* 11(10):1359-64, 2011. PMID: 21923256
215. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, Decuyper S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of antimony-resistant *Leishmania donovani* isolates: Biochemical and biophysical studies and interaction with host cells. *Int J Parasitol.* 41(13-14):1311-21, 2011. PMID: 21920365
216. Srivastava P, Singh T, Sundar S. Genetic Heterogeneity in Clinical Isolates of *Leishmania donovani* from India. *J Clin Microbiol.* 49(10):3687-90, 2011. PMID: 21865422
217. Gidwani K, Picado A, Rijal S, Singh SP, Roy L, Volfova V, Andersen EW, Uranw S, Ostyn B, Sudarshan M, Chakravarty J, Volf P, Sundar S, Boelaert M, Rogers ME. Serological Markers of Sand Fly Exposure to Evaluate

---

Insecticidal Nets against Visceral Leishmaniasis in India and Nepal: A Cluster-Randomized Trial. *PLoS Negl Trop Dis*. 5(9):e1296, 2011. PMID: 21931871

218. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, Sundar S, Sacks D. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. *J Infect Dis*. 204(7):1134-7, 2011. PMID: 21881130
219. Ouakad M, Vanaerschot M, Rijal S, Sundar S, Speybroeck N, Kestens L, Boel L, DE Doncker S, Maes I, Decuypere S, Dujardin JC. Increased metacyclogenesis of antimonyresistant *Leishmania donovani* clinical lines. *Parasitology*. 138(11):1392-9, 2011. PMID: 21819638
220. Meena LP, Rai M, Singh SK, Chakravarty J, Singh A, Goel R, Pathak A, Sundar S. Endocrine changes in male HIV patients. *J Assoc Physicians India*. 59:365-6, 371, 2011. PMID: 21751590
221. Fakiola M, Miller EN, Fadl M, Mohamed HS, Jamieson SE, Francis RW, Cordell HJ, Peacock CS, Raju M, Khalil EA, Elhassan A, Musa AM, Silveira F, Shaw JJ, Sundar S, Jeronimo SM, Ibrahim ME, Blackwell JM. Genetic and Functional Evidence Implicating *DLL1* as the Gene That Influences Susceptibility to Visceral Leishmaniasis at Chromosome 6q27. *J Infect Dis*. 204(3):467-77, 2011. PMID: 21742847
222. Chakravarty J, Kumar S, Kumar R, Gautam S, Rai M, Sundar S. Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. *Trans R Soc Trop Med Hyg*. 105(9):537-9, 2011. PMID: 21708392
223. Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of Oral Sitamaquine Taken with or without Food and Safety and Efficacy for Treatment of Visceral Leishmaniasis: A Randomized Study in Bihar, India. *Am J Trop Med Hyg*. 84(6):892-900, 2011. PMID: 21633025
224. Malaviya P, Singh RP, Singh SP, Hasker E, Ostyn B, Shankar R, Boelaert M, Sundar S. Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system. *Trop Med Int Health*. 16(9):1159-66, 2011. PMID: 21624015
225. Srivastava P, Prajapati VK, Rai M, Sundar S. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. *J Clin Microbiol*. 49:3088-91, 2011. PMID: 21613432
226. Mohan S, Srivastava P, Maheshwari SN, Sundar S, Prakash R. Nano-structured nickel oxide based DNA biosensor for detection of visceral leishmaniasis (Kala-azar). *Analyst*. 136:2845-51, 2011. PMID: 21611668
227. Sudarshan M, Weirather JL, Wilson ME, Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. *J Antimicrob Chemother*. 66:1751-5, 2011. PMID: 21609983
228. Mehrotra S, Oommen J, Mishra A, Sudharshan M, Tiwary P, Jamieson SE, Fakiola M, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. No evidence for association between *SLC11A1* and visceral leishmaniasis in India. *BMC Med Genet*. 12:71, 2011. PMID: 21599885
229. Srivastava P, Mehrotra S, Tiwary P, Chakravarty J, Sundar S. Diagnosis of Indian visceral leishmaniasis by nucleic Acid detection using PCR. *PLoS*
-

---

*One.* 6(4):e19304, 2011. PMID: 21559398

230. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-Gamma Release Assay (Modified QuantiFERON) as a Potential Marker of Infection for *Leishmania donovani*, a Proof of Concept Study. *PLoS Negl Trop Dis.* 5(4):e1042, 2011. PMID: 21526219
231. Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Lima MA, Ritmeijer K, Costa CH, Costa DL, Rijal S, Sundar S, Balasegaram M. Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia. *Am J Trop Med Hyg.* 84(4):543-550, 2011. PMID: 21460007
232. Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J. Visceral leishmaniasis: elimination with existing interventions. *Lancet Infect Dis.* 11(4):322-5, 2011. PMID: 21453873
233. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of Visceral leishmaniasis. *Vaccine.* 29(19):3531-7, 2011. PMID: 21414377
234. Kumar S, Kumar D, Chakravarty J, Sundar S. Identification and characterization of a novel 37 kDa *Leishmania donovani* Antigen for Diagnosis of Indian Visceral Leishmaniasis. *Clin Vaccine Immunol.* 18(5):772-5, 2011. PMID: 21411602
235. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S. Targeted killing of *Leishmania donovani* in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. *J Antimicrob Chemother.* 66(4):874-9, 2011. PMID: 21393222
236. Malaviya P, Picado A, Singh SP, Hasker E, Singh RP, Boelaert M, Sundar S. Visceral leishmaniasis in muzaffarpur district, bihar, India from 1990 to 2008. *PLoS One.* 6(3):e14751, 2011. PMID: 21394195
237. Vaish M, Mehrotra S, Chakravarty J, Sundar S. Noninvasive Molecular Diagnosis of Human Visceral Leishmaniasis. *J Clin Microbiol.* 49(5):2003-5, 2011. PMID: 21389158.
238. Ansari NA, Kumar R, Gautam S, Nysten S, Singh OP, Sundar S, Sacks D. IL-27 and IL-21 are associated with T Cell IL-10 responses in Human Visceral Leishmaniasis. *J Immunol.* 186(7):3977-85, 2011. PMID: 21357266
239. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D, Sundar S, Das P, Gurung CK, Rijal S, Thakur CP, Varghese B, Kroeger A. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and bangladesh, comparing yield, feasibility and costs. *PLoS Negl Trop Dis.* 5(5):e960, 2011. PMID: 21347452
240. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, noninferiority, randomised controlled trial. *Lancet.* 377 :477-86, 2011. PMID: 21255828
241. Fakiola M, Mishra A, Rai M, Singh SP, O'Leary RA, Ball S, Francis RW, Firth MJ, Radford BT, Miller EN, Sundar S, Blackwell JM. Classification and regression tree and spatial analyses reveal geographic
-

---

heterogeneity in genome wide linkage study of Indian visceral leishmaniasis. *PLoS One*. 5(12):e15807, 2010.PMID: 21209823

242. Picado A, Singh SP, Rijal S, Sundar S, Ostyn B, Chappuis F, Uranw S, Gidwani K, Khanal B, Rai M, Paudel IS, Das ML, Kumar R, Srivastava P, Dujardin JC, Vanlerberghe V, Andersen EW, Davies CR, Boelaert M. Longlasting insecticidal nets for prevention of *Leishmania donovani* infection in India and Nepal: paired cluster randomised trial. *BMJ*. 341:c6760, 2010.PMID: 21190965
243. Singodia D, Gupta GK, Verma A, Singh V, Shukla P, Misra P, Sundar S, Dube A, Mishra PR. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis. *J Biomed Nanotechnol*. 6(3):293-302, 2010.PMID: 21179947
244. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.. *Indian J Med Res*. 132:386-9, 2010.PMID: 20966515
245. Dujardin JC, Herrera S, do Rosario V, Arevalo J, Boelaert M, Carrasco HJ, Correa-Oliveira R, Garcia L, Gotuzzo E, Gyorkos TW, Kalergis AM, Kouri G, Larraga V, Lutumba P, Macias Garcia MA, Manrique-Saide PC, Modabber F, Nieto A, Pluschke G, Robello C, Rojas de Arias A, Rumbo M, Santos Preciado JI, Sundar S, Torres J, Torrico F, Van der Stuyft P, Victoir K, Olesen OF. Research priorities for neglected infectious diseases in Latin America and the Caribbean region. *PLoS Negl Trop Dis*. 4(10):e780, 2010.PMID: 21049009
246. Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, Lejon V, Chappuis F, Boelaert M, Sundar S. Note: Persistence of *Leishmania donovani* antibodies in past Visceral Leishmaniasis cases in India. *Clin Vaccine Immunol*. 18(2):346-8, 2010. PMID: 21159922
247. Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. *Trans R Soc Trop Med Hyg*. 105(2):115-7. PMID: 21129762
248. Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S. Detection of *Leptomonas* sp. parasites in clinical isolates of Kala-azar patients from India. *Infect Genet Evol*. 10 :1145–1150, 2010. PMID: 20633704
249. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M. Costeffectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. *PLoS Negl Trop Dis*. 4(9), 2010. pii: e818.PMID: 20838649
250. Agarwal D, Narayan S, Chakravarty J, Sundar S. Ultrasonography for diagnosis of abdominal tuberculosis in HIV infected people. *Indian J Med Res*. 132: 77-80, 2010 .PMID: 20693594
251. Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of *Leishmania donovani*. *Br J Clin Pharmacol*. 70 :609-17, 2010. PMID: 20840452
252. Hirve S, Singh SP, Kumar N, Banjara MR, Das P, Sundar S, Rijal S, Joshi A, Kroeger A, Varghese B, Thakur CP, Huda MM, Mondal D. Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. *Am J*
-

*Trop Med Hyg.* 83 :507-11, 2010. PMID: 20810811

253. Singh DP, Goyal RK, Singh RK, Sundar S, Mohapatra TM. In search of an ideal test for diagnosis and prognosis of kala-azar. *J Health Popul Nutr.* 28(3):281-5, 2010. PMID: 20635639
254. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, Nylén S. Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3<sup>+</sup> CD4 cells in blood or spleen. *Parasite Immunol.* 32: 479-83, 2010. PMID: 20591118
255. Hasker E., Singh SP, Malaviya P, Singh RP, Shankar R, Boelaert M, Sundar S. Management of visceral leishmaniasis in rural primary health care services in Bihar, India *Trop Med Int Health.* 15 Suppl 2:55-62, 2010. PMID: 20591081
256. Mishra RN, Singh SP, Vanlerberghe V, Sundar S, Boelaert M, Lefevre P. Lay perceptions of kala-azar, mosquitoes and bed nets in Bihar, India. *Trop Med Int Health.* 15 (Suppl):36- 41, 2010. PMID: 20591080
257. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of trypanothione peroxidase in antimony unresponsive *Leishmania donovani* field isolates. *Mol Biochem Parasitol.* 173(2):162-4, 2010. PMID: 20553768
258. Kaur J, Sundar S, Singh N. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of *Leishmania donovani*. *J Antimicrob Chemother.* 65(8):1742-8, 2010. PMID: 20519355
259. Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of Blood agar micro-titer plates for culturing *Leishmania* parasites to titrate the parasite burden in spleen and peripheral blood of VL patients. *Clin. Microbiol.* 48(5):1932-4, 2010. PMID: 20335419
260. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. *N Engl J Med.* 362: 504-12, 2010. PMID: 20147716
261. Singh SP, Hasker E, Picado A, Gidwani K, Malaviya P, Singh RP, Boelaert M, Sundar S. Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. *Trop Med Int Health.* 15 (Suppl):29-35, 2010. PMID: 20487424
262. Singh SP, Picado A, Boelaert M, Gidwani K, Andersen EW, Ostyn B, Meheus F, Rai M, Chappuis F, Davies C, Sundar S. The epidemiology of *Leishmania donovani* infection in high transmission foci in India. *Trop Med Int Health.* 15 (Suppl):12-20, 2010. PMID:20487420
263. Sundar S, Arora R, Singh SP, Boelaert M, Varghese B. Household-cost-of-illness of visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 15 (Suppl):50-54 , 2010. PMID: 20487419
264. Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. *Am J Trop Med Hyg.* 82(5):808-13, 2010. PMID: 20439959
265. Clements MF, Gidwani K, Kumar R, Hostomska J, Dinesh DS, Kumar V, Das P, Muller I, Hamilton G, Volfova V, Boelaert M, Das M, Rijal S, Picado A, Volf P, Sundar S, Davies CR, Rogers ME. Measurement of recent exposure to *Phlebotomus argentipes*, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. *Am J*

---

*Trop Med Hyg.* 82(5):801-7, 2010. PMID: 20439958

266. Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S. Comparative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. *J Infect Dev Ctries.* 4:114-7, 2010. PMID: 20439958
267. Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR. Effect of Village-wide Use of Long- Lasting Insecticidal Nets on Visceral Leishmaniasis Vectors in India and Nepal: A Cluster Randomized Trial. *PLoS Negl Trop Dis.* 4(1): e587, 2010. PMID: 20126269
268. Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR. Effect of Village-wide Use of Long- Lasting Insecticidal Nets on Visceral Leishmaniasis Vectors in India and Nepal: A Cluster Randomized Trial. *PLoS Negl Trop Dis.* 4(1): e587, 2010. PMID: 20126269
269. Sundar S, Chakravarty J. Antimony Toxicity. *Int. J. Environ. Res. Public Health.* 7(12):4267-77, 2010. PMID: 21318007
270. Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 105(1):1-6, 2010. PMID: 21074233
271. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. *J Glob Infect Dis.* (2):159-66, 2010. PMID: 20606972
272. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. *J Glob Infect Dis.* 2(2):167-76, 2010. PMID: 20606973
273. Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing *Leishmania* species of visceral and cutaneous forms. *Acta Trop.* 113(2):202-6, 2009. PMID: 19854144
274. Picado A, Kumar V, Das M, Burniston I, Roy L, Suman R, Dinesh D, Coosemans M, Sundar S, Shreekant K, Boelaert M, Davies C, Cameron M. Effect of untreated bed nets on blood-fed *Phlebotomus argentipes* in kala-azar endemic foci in Nepal and India. *Mem Inst Oswaldo Cruz.* 104: 1183-1186, 2009. PMID: 20140382
275. Singh DP, Sundar S, Mohapatra TM. The rK39 strip test is non-predictor of clinical status for kala-azar. *BMC Res Notes.* 2:187, 2009. PMID: 19772616
276. Vanlerberghe V, Singh SP, Paudel IS, Ostyn B, Picado A, Sanchez A, Rijal S, Sundar S, Davies C, Boelaert M. Determinants of bednet ownership and use in visceral leishmaniasis endemic areas of the Indian subcontinent. *Trop Med Int Health.* 15(1):60-7, 2009. PMID: 19917036
277. Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment. *Clin Infect Dis.* 49:914-8, 2009. PMID: 19663597
278. Sundar S, Singh A, D. Agarwal, M. Rai, N. Agrawal, and J. Chakravarty. Safety and Efficacy of High-Dose Infusions of a Preformed Amphotericin B Fat Emulsion for Treatment of Indian Visceral Leishmaniasis. *Am. J. Trop. Med. Hyg.* 80: 700-703, 2009. PMID: 19407109
279. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14:918-25, 2009. PMID: 19563434
280. Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A. Transgenic *Leishmania donovani* clinical isolates expressing green fluorescent protein

- constitutively for rapid and reliable ex vivo drug screening. *J Antimicrob Chemother.* 64:370-4, 2009. PMID: 19525291
281.       Gidwani K, Rai M, Chakravarty J, Boelaert M, Sundar S. Evaluation of leishmanin skin test in Indian visceral leishmaniasis. *Am J Trop Med Hyg.* 80:566-7, 2009. PMID: 19346376
282.       Sarkar A, Mandal G, Singh N, Sundar S, Chatterjee M. Flow cytometric determination of intracellular non-protein thiols in *Leishmania* promastigotes using 5-chloromethyl fluorescein diacetate. *Exp Parasitol.* 122 : 299–305, 2009. PMID: 19393240
283.       Boelaert M, Meheus F, Sanchez A, Singh SP, Vanlerberghe V, Picado A, Meessen B, Sundar S. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14: 639 644, 2009. PMID: 19392741
284.       Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A, Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME. Genetics and visceral leishmaniasis: of mice and man. *Parasite Immunol.* 31:254-66, 2009. PMID: 19388946
285.       Gidwani K, Kumar R, Rai M, Sundar S. Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. *Am J Trop Med Hyg.* 80: 345-6, 2009. PMID: 19270279
286.       Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M. Visceral Leishmaniasis Elimination Programme in India, Bangladesh, and Nepal: Reshaping the Case Finding/Case Management Strategy. *PLoS Negl Trop Dis.* 3: e355, 2009. PMID: 19159009
287.       Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M. Functionality of drug efflux pumps in antimonial resistant *Leishmania donovani* field isolates. *Indian J Biochem Biophysics.* 46; 86-92, 2009. PMID: 19374259
288.       Ghoshal A, Mukhopadhyay S, Demine R, Forger M, Jarmalavicius S, Saha B, Sundar S, Walden P, Mandal C, Mandal C. Detection and characterization of a sialoglycosylated bacterial ABC-type phosphate transporter protein from patients with visceral leishmaniasis. *Glycoconj J.* 26:675-89, 2009. PMID: 19184417
289.       Awanish Kumar, Vijay Raju Boggula, Shyam Sundar, Ajit Kumar Shasany and Anuradha Dube. Identification of genetic markers in Sodium Antimony Gluconate (SAG) sensitive and resistant Indian clinical isolates of *Leishmania donovani* through amplified fragment length polymorphism (AFLP). *Acta Tropica.* 110: 80–85, 2009. PMID: 19283900
290.       Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. *Trop Med Int Health.* 14 : 88–92, 2009. PMID: 19121150
291.       Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine. *Clin Infect Dis.* 47: 1000-1006, 2008. PMID: 18781879
292.       Alam MZ, Kuhls K, Schweynoch C, Sundar S, Rijal S, Shamsuzzaman AK, Raju BV, Salotra P, Dujardin JC, Schonian G. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of *Leishmania donovani* strains in the Indian subcontinent. *Infect Genet Evol.* 9:24-31, 2008. PMID: 18957333
293.       Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ.



---

Intracellular Survival of Leishmania Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors. *J Infect Dis.* 198: 1292-9, 2008. PMID: 18816190

294. Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S. Prophylactic Efficacy of High- Molecular-Weight Antigenic Fractions of a Recent Clinical Isolate of Leishmania donovani Against Visceral Leishmaniasis. *Scand J Immunol.* 68: 492-501, 2008. PMID: 18803606
295. Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. *Vaccine.* 26 :4813–4818, 2008. PMID: 18656517
296. Tuli L, Gulati AK, Sundar S, Mohapatra TM. Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - An experience of a tertiary care hospital in Varanasi (India). *BMC Gastroenterol.* 8 :36, 2008. PMID: 18713475
297. Chakraborty D, Basu JM, Sen P, Sundar S, Roy S. Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial. *Ann Trop Med Parasitol.* 102 :21-38, 2008. PMID: 18186975
298. Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N , Rai M. Safety of a preformulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. *Trop Med Int Health.* 13: 1208–1212, 2008. PMID: 18664241
299. Agarwal D, Chakravarty J, Sundar S, Gupta V, Bhatia BD. Correlation between clinical features and degree of immunosuppression in HIV infected children. *Indian Pediatr.* 45:140-3, 2008. PMID: 18310794
300. Ostyn B, Vanlerberghe V, Picado A, Dinesh DS, Sundar S, Chappuis F, Rijal S, Dujardin JC, Coosemans M, Boelaert M, Davies C. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? *Trop Med Int Health.* 13 :1073-85, 2008. PMID: 18564350
301. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. *J Antimicrob Chemother.* 62: 376-80, 2008. PMID: 18453526
302. Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. *Trans R Soc Trop Med Hyg.* 102, 32- 40, 2008. PMID: 17942129
303. Attili SVS, Singh VP, Rai M, Varma DV , Gulati AK, Sundar S. Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Varanasi, North India. *Turk J Hematol.* 25:13-19, 2008. PMID: 27264145
304. Dwivedi US, Kumar A, Das SK, Trivedi S, Kumar M, Sundar S, Singh PB. Relook TURBT in superficial bladder cancer: Its importance and its correlation with the tumor ploidy. *Urol Oncol.* 27:514-9, 2008. PMID: 18639472
305. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A .Proteomic approaches for discovery & new targets for vaccine and therapeutics against visceral leishmaniasis. *Proteomics Clinical Applications.* 3 : 372-386, 2008. PMID: 21136840
-

306. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal – the challenges for diagnosis and treatment. *Trop Med Int Health*. 13: 2–5, 2008. PMID: 18290995
307. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. *Expert Opin Investig Drugs*. 17:787-94, 2008. PMID: 18447603
308. Sundar S, Olliaro P. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. *Thera Clin Risk Management*. 3: 733-40, 2007. PMID: 18472998
309. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat Rev Microbiol*. 11:873-82, 2007. PMID: 17938629
310. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. *N Engl J Med*. 356:2571-81, 2007. PMID: 17582067
311. Tripathi K, Kumar R, Bharti K, Kumar P, Shrivastav R, Sundar S, Pai K. Adenosine deaminase activity in sera of patients with visceral leishmaniasis in India. *Clin Chim Acta*. 388: 135-8, 2007. PMID: 18023276
312. Das ML, Singh SP, Vanlerberghe V, Rijal S, Rai M, Karki P, Sundar S, Boelaert M. Population Preference of Net Texture prior to Bed Net Trial in Kala-Azar–Endemic Areas. *Plos Neg Trop Dis*. 1: e100, 2007. PMID: 18160976
313. Basu JM, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection. *Antimicrob Agents Chemother*. 52:1080-93, 2007. PMID: 18056276
314. Sundar S, Singh RK, Bimal SK, Gidwani K, Mishra A, Maurya R, Singh SK, Manandhar KD, Boelaert M, Rai M. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. *Trop Med Int Health*. 12: 284-9, 2007. PMID: 17300637
315. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate- Day Infusions. *Clin Infect Dis*. 45: 556-61, 2007. PMID: 17682988
316. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. *J Infect Dis*. 196:591-8, 2007. PMID: 17624846
317. Mandal G, Wyllie S, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. *Parasitology*. 134:1679-87, 2007. PMID: 17612420
318. Mittal MK, Rai S, Ashutosh, Ravinder, Gupta S, Sundar S, Goyal N. Characterization of natural antimony resistance in leishmania donovani isolates. *Am J Trop Med Hyg*. 76 :681- 8, 2007. PMID: 17426170
319. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. *J Exp Med*. 204 :

---

805-17, 2007. PMID: 17389235

320. Samant M, Sahasrabudde AA, Singh N, Gupta SK, Sundar S, Dube A. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of *Leishmania donovani*. *Parasitology*. 16:1-10, 2007. PMID: 17362540
321. Hide M, Singh R, Kumar B, Banuls AL, Sundar S. A microculture technique for isolating live *Leishmania* parasites from peripheral blood of visceral leishmaniasis patients. *Acta Trop*. 102:197-200, 2007. PMID: 17544353
322. Singh N, Almeida R, Kothari H, Kumar P, Mandal G, Chatterjee M, Venkatachalam S, Govind MK, Mandal SK, Sundar S. Differential gene expression analysis in antimonyunresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. *Parasitology*. 134: 777-87, 2007. PMID: 17306059
323. Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in *Leishmania*. *J Med Microbiol*. 56:143-53, 2007. PMID: 17244793
324. Kumar P, Sundar S, Singh N. Degradation of pteridine reductase 1 (PTR1) enzyme during growth phase in the protozoan parasite *Leishmania donovani*. *Exp Parasitol*. 116:182-9, 2007. PMID: 17275814
325. Shrivastava R, Sinha PR, Singh VP, Sundar S. Echocardiographic evaluation of cardiac status in Indian visceral leishmaniasis patients. *Trans R Soc Trop Med Hyg*. 101: 429-32, 2007. PMID: 17049574
326. Attili VS, Singh VP, Sundar S, Mehta H, Negi ML, Gogia A, Raju SH, Rai M. Malignant myelomatous pleural effusion with good response to combination chemotherapy. *J Assoc Physicians India*. 55:595-6, 2007. PMID: 18019805
327. Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V. Cure of Antimony Unresponsive Indian Post Kala-azar Dermal Leishmaniasis with Oral Miltefosine. *Tran Roy Soc Trop Med Hyg*. 100: 698-700, 2006. PMID: 16325873
328. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in *Leishmania donovani* clinical field isoaltes by modulating drug-induced programmed cell death. *Molecular & Cellular Proteomics*. 6:88-101, 2006. PMID: 17050524
329. Jacquet, D, Boelaert M, Seaman J, Rijal S, Sundar S, Menten J, Magnus, E. Comparative evaluation of freeze dried and liquid antigens in the Direct Agglutination Test for serodiagnosis of Visceral Leishmaniasis (ITMA-DAT/VL). *Trop Med Int Health*. 11:1777- 84, 2006. PMID: 17176341
330. Forgber M, Basu R, Theinert S, Roy S, Sundar S, Walden P. Mapping by proteome serology the antigenicity of the parasites in *Leishmania donovani* infection. *PLoSone*. 1: e40, 2006. PMID: 17183669
331. Kothari H, Kumar P, Sundar S, Singh N. Possibility of membrane modification as a mechanism of antimony resistance in *Leishmania donovani*. *Parasitol Int*. 56:77-80, 2006. PMID: 17169604
332. Chakravarty J, Mehta H, Parekh A, Attili SVS, Agrawal NR, Singh SP, Sundar S. Study on Clinico-epidemiological Profile of HIV Patients in Eastern India. *J Assoc Physicians India*. 54: 854-857, 2006. PMID: 17249252
333. Meheus F, Boelaert M, Baltussen R, Sundar S. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. *Trop Med Int Health*. 11:1715-24, 2006. PMID: 17054752
-

334. Kothari H, Kumar P, Saluja R, Sundar S, Singh N. Translation of open reading frame in kinetoplast DNA minicircles of clinical isolates of *L. donovani*. *Parasitol Res.* 100: 893-7, 2006. PMID: 17047999
335. Singh SP, Reddy DC, Mishra RN, Sundar S. Knowledge, attitude, and practices related to kala-azar in a rural area of Bihar state, India. *Am J Trop Med Hyg.* 75: 505-8, 2006. PMID: 16968930
336. Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M. Amphotericin B Colloidal Dispersion (ABCD) in the Treatment of Indian Visceral Leishmaniasis. *Clin Infect Dis.* 42:608–13, 2006. PMID: 16447104
337. Sundar S, Singh R K, Maurya R S, Kumar B, Chhabra A, Singh V, Rai M. Serological Diagnosis of Indian Visceral Leishmaniasis – Direct Agglutination test versus rK39 strip test. *Trans Roy Soc Trop Med Hyg.* 100:533-537, 2006. PMID: 16325874
338. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. Rapid Noninvasive Diagnosis in Indian Visceral Leishmaniasis: Comparison of Two Strip Test Formats in Detection of Anti-K39 Antibody. *J Clin Microbiol.* 44 :251- 3, 2006. PMID: 16390983
339. Perez-Victoria FJ, Sanchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F. Mechanisms of experimental resistance of *Leishmania* to miltefosine: Implications for clinical use. *Drug Resistance Updates.* 9: 26–39, 2006. PMID: 16814199
340. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 100: s26-33, 2006. PMID: 12792385
341. Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA. Miltefosine: issues to be addressed in the future. *Trans R Soc Trop Med Hyg.* 100 :S41-4, 2006. PMID: 16750231
342. Singh SP, Reddy DCS, Rai M, Sundar S. Serious underreporting of Visceral Leishmaniasis through passive case reporting in Bihar, India. *Trop Med Intl Health.* 11: 899-905, 2006. PMID: 16772012
343. SV S Attili, Gulati AK, Singh VP, Varma DV, Rai M, Sundar S. Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. *BMC Infectious Diseases.* 6:39, 2006. PMID: 16509972
344. Tripathi P, Ray S, Sundar S, Dube A, Naik S. Identification of *Leishmania donovani* antigens stimulating cellular immune responses in exposed immune individuals. *Clin Exp Immunol.* 143:380–388, 2006. PMID: 16412064
345. Garg R, Shraddha K, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A. *Leishmania donovani*: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis *Vaccine.* 24:2900-9, 2006. PMID: 16448729
346. Kumar R, Pai K, P. Kumar P, Pandey HP, S. Sundar S. Sero-epidemiological study of kalaazar in a village of Varanasi district, India. *Trop Med Int Health.* ;11:41-48, 2006. PMID:16398754
347. Lockwook DNJ, Sundar S. Serological tests for visceral leishmaniasis - have high sensitivity, but several limitations. (*Editorial*) *BMJ.* 711-2, 2006. PMID: 17023436
-

348. Lockwook DNJ, Sundar S. Serological tests for visceral leishmaniasis - have high sensitivity, but several limitations. (*Editorial*) *BMJ*. 711-2, 2006. PMID: 17023436
349. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. *Clin Infect Dis*. 43: 917-24, 2006. PMID: 16941377
350. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. *Indian J Med Res*. 123: 345-352, 2006. PMID: 16778315
351. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): Challenges ahead. *Indian J Med Res*. 123: 331-344, 2006. PMID: 16778314
352. Agrawal S, Rai M, Sundar S. Management of visceral leishmaniasis: Indian perspective. *J Postgrad Med*. 51 (suppl): S53-57, 2005. PMID: 16519257
353. Olliaro PL, Guerin PL, Gerstl S, Haaskjold AA, Rottingen J, Sundar S. Treatment options for visceral leishmaniasis: lessons from a review of clinical studies conducted in India during 1980-2004. *Lancet Infect Dis*. 5:763-74, 2005. PMID: 16310148
354. Sundar S, Rai M. The Treatment of Visceral Leishmaniasis. *Expert Opinion Pharmacotherapy*. 6:2821-9, 2005. PMID:16318433
355. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J. A Phase II Dose-Ranging Study of Sitamaquine for the Treatment of Visceral Leishmaniasis In India. *Amer J Trop Med Hyg*. 73:1005-1011, 2005. (Joint first authors). PMID: 16354802
356. Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB. Sodium stibogluconate resistance in *Leishmania donovani* correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. *Parasitology*. 131: 747-57, 2005. PMID: 16336728
357. Barnett PG, Singh SP, Bern C, Hightower AW, Sundar S. Virgin Soil: The Spread of Visceral Leishmaniasis into Uttar Pradesh, India. *Amer J Trop Med Hyg*. 73 :720-725, 2005. PMID: 16222016
358. Theinert SM, Basu R, Forgher M, Roy S, Sundar S, Walden P. Identification of New Antigens in Visceral Leishmaniasis by Expression Cloning and Immunoblotting with Sera of Kala-Azar Patients from Bihar, India. *Infec Immun*. 73: 7018-21, 2005. PMID: 16177384
359. Ashutosh, Gupta S, Ramesh, Sundar S, Goyal N. Use of *Leishmania donovani* Field Isolates Expressing the Luciferase Reporter Gene in In Vitro Drug Screening. *Antimicrob Agents Chemother*. 49: 3776-83, 2005. PMID: 16131481
360. Sundar S, Agrawal S, Pai K, Chance M, Hommel M. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by latex agglutination test (KAtex). *Amer J Trop Med Hyg*. 73: 269-271, 2005. PMID: 16103587
361. Maurya R, Singh RK, Kumar B, Salotra P, Rai M, Sundar S. Evaluation of PCR in the diagnosis of Indian kala-azar and assessment of cure. *J Clin Micro*. 43:3038-41, 2005. PMID: 16000412
362. Manna M, Majumder HK, Sundar S, Bhaduri AN. The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR. *Med Sci Monit*. 11:BR220-227, 2005. PMID: 15990683
363. Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and

- 
- in vivo experimental models. *Parasitol Res.* 96: 216–223, 2005. PMID: 15868188
364. Attili VS, Singh VP, Rai M, Varma DV, Sundar S. Evaluation of the status of tuberculosis as part of the clinical case definition of AIDS in India. *Postgrad Med J.* 81:404-8, 2005. PMID: 15937209
365. Garg R, Gupta SK, Tripathi P, Naik S, Sundar S, Dube A. Immunostimulatory cellular responses of cured Leishmania infected patients and hamsters against the Integral Membrane Proteins and Non Membranous Soluble Proteins of recent clinical isolate of Leishmania donovani. *Clin Exp Immunol.* 140:149–156, 2005. PMID: 15762886
366. Sundar S, Kumar A. Challenges in the Management of Visceral Leishmaniasis (Editorial). *Indian Ped.* 42: 523-6, 2005. PMID: 15995268
367. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India (Perspective). *Bull WHO.* 83(5):394-5, 2005. PMID:15976883
368. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray H W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. *Clin Infect Dis.* 38 : 377-83, 2004. PMID: 14727208
369. Bommer W, Eibl HJ, Engel KR, Kuhlencord A, Sindermann H, Sundar S, Zappel H. Leishmaniasis--oral treatment with hexadecylphosphocholine. *Wien Klin Wochenschr.* 116 Suppl 4:24-9, 2004. PMID: 15683039
370. Bandyopadhyay S, Chatterjee M, Das T, Sundar S, Mandal C. Antibodies Directed Against O-Acetylated Sialoglycoconjugates Accelerate Complement Activation in Leishmania donovani Promastigotes. *J Infect Dis.* 190: 2010-9, 2004. PMID: 15529267
371. Bandyopadhyay S, Chatterjee M, Pal S, Waller RF, Sundar S, McConville MJ and Mandal C. Purification, characterization of O-acetylated sialoglycan specific IgM and development of an enzyme linked immunosorbent assay for serodiagnosis of Indian Visceral Leishmaniasis patients. *Diag Microbiol Inf Dis.* 50:15–24,2004. PMID: 15380274
372. Bandhyopadhyay S, Chatterjee M, Sundar S and Mandal C. Identification of 9-Oacetylated sialoglycans on peripheral blood mononuclear cells in Indian Visceral Leishmaniasis. *Glycoconjugate Journal.* 20: 531–536, 2004. PMID: 15454691
373. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. *J Biol Chem.* 279: 31010-7, 2004. PMID: 15138256
374. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. *Clin Infect Dis.* 38:217-21, 2004. PMID: 14699453
375. Chava AK, Chatterjee M, Sharma V, Sundar S, Mandal C. Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-o-acetylated sialoglycans. *J Infect Dis.* 189:1257-64, 2004. PMID: 15031795
376. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. *Clin Infect Dis.* 37: 800-4, 2003. PMID: 12955641
377. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in
-

- kala-azar field isolates. *J Infect Dis.* 188: 600-7, 2003. PMID: 12898450
378. Sundar S. Diagnosis of kala-azar – An important stride Editorial. *J Assoc Physicians India.* 51: 753-5, 2003. PMID: 14651132
379. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. *Pediatr Infect Dis J.* 22: 434-8, 2003. PMID: 12792385
380. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of *Leishmania donovani* to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. *Antimicrob Agents Chemother.* 47: 1529-35, 2003. PMID: 12709318
381. Davies CR, Kaye P, Croft SL, Sundar S 2003. Leishmaniasis: new approaches to disease control. *BMJ.* 326(7385):377-82, 2003. PMID: 12586674
382. Sundar S, Benjamin B. Diagnosis and treatment of Indian visceral leishmaniasis. *J Assoc Physicians India.* 51:195-201, 2003. PMID: 12725267
383. Sundar S. Indian kala-azar – Better tools needed for diagnosis and treatment. *J Postgrad Med.* 49: 29-30, 2003. PMID: 12865568
384. Sundar S, Rai M. Advances in the treatment of leishmaniasis. *Curr Opin Infect Dis.* 15: 593-8, 2002. PMID: 12821836
385. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. *Clin Diagn Lab Immunol.* 9: 951-8, 2002. PMID: 12204943
386. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. *Lancet Infect Dis.* 2(8):494-501, 2002. PMID: 12150849
387. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. *N Engl J Med.* 347: 1739-46, 2002. PMID: 12792385
388. Kumar P, Pai K, Pandey HP, Sundar S. NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. *J Med Microbiol.* 51: 832- 6, 2002. PMID: 12435061
389. Eidsmo L, Wolday D, Berhe N, Sabri F, Satti I, El Hassan AM, Sundar S, Chiodi F, Akuffo H. Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. *Clin Exp Immunol.* 130: 307-13, 2002. PMID: 12390320
390. Chava AK, Chatterjee M, Sundar S, Mandal C. Development of an assay for quantification of linkage-specific O-acetylated sialoglycans on erythrocytes its application in Indian visceral leishmaniasis. *J Immunol Methods.* 270: 1-10, 2002. PMID: 12379333
391. Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S 2002. Immunoblot analysis of the humoral immune response to *Leishmania donovani* polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. *Clin Diagn Lab Immunol.* 9: 1119-23, 2002. PMID: 12204969
392. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, Berman JD, Murray HW. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. *Clin Infect Dis.* 35: 581-6, 2002. PMID: 12173133
393. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. *Am J Trop Med Hyg.* 66: 143-6, 2002. PMID: 12135284
394. Sundar S, Pai K, Sahu M, Kumar V, Murray HW.

Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. *Ann Trop Med Parasitol.* 96 : 19-23, 2002. PMID: 11989529

395. Singh N, Singh RT, Sundar S. Identification of a gene linked to drug resistance in field isolates of *Leishmania donovani*. *Ann Trop Med Parasitol.* 96: 839-41, 2002. PMID: 12625940
396. Rai M, Srinivasan A, Sundar S, Singh VP. Cyclosporine-induced reversible pure motor spastic paraparesis in a patient with aplastic anaemia. *J Assoc Physicians India.* 50: 133-7, 2002. .PMID: 12568232
397. Singh VP, Rai M, Shukla J, Sundar S, Usha. Chronic lymphocytic leukaemia terminating into plasma cell leukemia. *J Assoc Physician India.* 50: 840-1, 2002. PMID: 12240859
398. Singh VP, Khanna A, Rai M, Sundar S, Shukla PK, Naresh T, Shukla J. Non-Hodgkin's lymphoma with pure red cell aplasia. *J Assoc Physicians India.* 49: 1123-4, 2001. PMID: 11868873
399. Pai K, Sundar S. A simple and inexpensive "cell dissociation sieve-tissue grinder" apparatus. *Indian J Exp Biol.* 39: 483-4, 2001. PMID: 11510135
400. Sundar S. Liposomal amphotericin B Letter. *Lancet .* 357: 801-2,2001.PMID: 11253992
401. Rai M, Singh VP, Shukla J, Sundar S, Jha VC. Low dose cyclosporine-a therapy in severe aplastic anaemia. *J Assoc Physicians India.* 49: 966-9, 2001. PMID: 11848327
402. Carter KC, Mullen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of *Leishmania donovani*. *Antimicrob Agents Chemother.* 45: 3555-9, 2001. PMID: 11709339
403. Salotra P, Sreenivas G, Ramesh V, Sundar S. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. *Br J Dermatol.* 145: 630-2, 2001. PMID: 11703291
404. Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral eishmaniasis. *Clin Diagn Lab Immunol.* 8: 1220-4, 2001. PMID: 11687466
405. Sundar S, Pai K, Kumar R, Pathak-Tripathi K, Gam AA, Ray M, Kenney RT. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. *Am J Trop Med Hyg.* 65: 193-6, 2001. PMID: 11561703
406. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. *BMJ.* 323: 419-22, 2001. PMID: 11520836
407. Kumar R, Pai K, Sundar S. Reactive oxygen intermediates, nitrite and IFN-( in Indian visceral leishmaniasis. *Clin Exp Immunol.* 124 : 262-5, 2001. PMID: 11422203
408. Sundar S. Treatment of visceral leishmaniasis. *Med Microbiol Immunol Berl.* 190: 89-92, 2001. .PMID: 11770119
409. Sundar S. Drug resistance in Indian visceral leishmaniasis. *Trop Med Int Health.* 6: 849- 54, 2001. PMID: 11703838
410. Mandal AK, Singh VP, Gulati AK, Sundar S, Mohapatra SC, Gupta KK, Matah SC, Rai M. Prevalence of human immunodeficiency virus infection in and around Varanasi, Uttar Pradesh, India. *J Assoc Physicians India.* 48



:288-9, 2000. PMID: 11229111

411. Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P, Murray HW. Short-course of oral miltefosine for treatment of visceral leishmaniasis. *Clin Infect Dis.* 31: 1110-3, 2000. PMID: 11049800
412. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. *Clin Infect Dis.* 31: 1104-7, 2000. PMID: 11049798
413. Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 94: 200-4, 2000. PMID: 10897369
414. Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. *J Assoc Physicians India.* 47: 186 8, 1999. PMID: 10999086
415. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. *Ann Trop Med Parasitol.* 93: 589-97, 1999. PMID: 10707104
416. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. *N Engl J Med.* 341: 1795-800, 1999. Shared first authorship. PMID: 10588964
417. Singh N, Curran MD, Rastogil AK, Middleton D, Sundar S. Diagnostic PCR with *Leishmania donovani* specificity using sequences from the variable region of kinetoplast minicircle DNA. *Trop Med Int Health.* 4: 448-53, 1999. PMID: 10444321
418. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimonyresistant strains of *Leishmania donovani*. *J Infect Dis.* 180: 564-7, 1999. PMID: 10395884
419. Chatterjee M, Jaffe CL, Sundar S, Basu D, Sen S, Mandal C. Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India. *Clin Diagn Lab Immunol.* 6: 550-4, 1999. PMID: 10391861
420. Kumar R, Kumar P, Chowdhary RK, Pai K, Mishra CP, Kumar K, Pandey HP, Singh VP, Sundar S. Kala-azar epidemic in Varanasi district, India. *Bull World Health Organ.* 77: 371-4, 1999. PMID: 10361752
421. Chatterjee M, Sharma V, Mandal C, Sundar S, Sen S. Identification of antibodies directed against O-acetylated sialic acids in visceral leishmaniasis: its diagnostic and prognostic role. *Glycoconj J.* 15: 1141-7, 1998. PMID: 10372969
422. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimonyunresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. *Ann Trop Med Parasitol.* 92(7):755-64, 1998. PMID: 9924533
423. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. *Lancet.* 352: 1821-3, 1998. PMID: 9851383
424. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP. *Am J Trop Med Hyg.* 59: 139-43, 1998. PMID:

9684642

425. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. *J Infect Dis*. 177: 815-8, 1998. PMID: 9498473
426. Sundar S, Reed SG, Singh VP, Kumar PC, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. *Lancet*. 351: 563-5, 1998. PMID: 9492776
427. Sundar S, Murray HW. Costs of Amphotericin B Lipid Complex for kala-azar Letter. *Ann Intern Med*. 128: 26, 1998. PMID: 9471948
428. Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, Murray H. Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar Letter. *Clin Infect Dis*. 27:215-6, 1998. PMID: 9675482
429. Sundar S, Singh VP, Dube RK, Dube B, Agrawal NR. Chronic neutrophilic leukaemia: a case report. *J Assoc Physicians India*. 36: 389-90, 1998. PMID: 3182716
430. Singh S, Sundar S, Singh VP. Leishmaniasis: recent advances in treatment Letter. *J Am Acad Dermatol*. 37: 512-3, 1997. PMID: 9308581
431. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. *J Infect Dis*. 176: 1117- 9, 1997. PMID: 9333181
432. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G. Antibody response against a *Leishmania donovani* amastigote-stage-specific protein in patients with visceral leishmaniasis. *Clin Diagn Lab Immunol*. 4: 530-5, 1997. PMID: 9302200
433. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. *Ann Intern Med*. 15 127: 133-7, 1997. PMID: 9230003
434. Singh N, Sundar S, Williams F, Curran MD, Rastogi A, Agrawal S, Middleton D. Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. *Trop Med Int Health*. 2 :468-71, 1997. PMID: 9217702
435. Singh N, Sundar S, Williams F, Curran MD, Rastogi A, Agrawal S, Middleton D. Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. *Trop Med Int Health*. 2 :468-71, 1997. PMID: 9217702
436. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. *J Infect Dis*. 173: 762-5, 1996. PMID: 8627049
437. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole Letter. *Lancet*. 348: 614, 1996. PMID: 8774589
438. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. *J Infect Dis*. 172: 1627-9, 1995. PMID: 7594733
439. Singh S, Singh R, Sundar S. Failure of ketoconazole in oriental sore in India. *J Chemother*. Suppl 4:202-3, 1995. PMID: 8904156
440. Dube B, Arora A, Singh VP, Kumar K, Sundar S. Platelet function studies in Indian kalaazar. *J Trop Med Hyg*. 98: 166-8, 1995. PMID: 7783273
441. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. *J Infect Dis*. 171: 992-6, 1995. PMID: 7706829

442. Singh S, Singh R, Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. *Int J Dermatol.* 34: 120-1, 1995. PMID: 7737771
443. Sundar S, Murray HW 1995. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. *J Assoc Physicians India.* 43(5):348-50, 1995. PMID: 9081967
444. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. *J Infect Dis.*170: 659-62, 1994. PMID: 8077725
445. Singh S, Sundar S. Treatment of post-kala-azar dermal leishmaniasis Letter. *Int J Dermatol.* 34: 668-9, 1995. PMID: 7591476
446. Vinayak VK, Mahajan D, Sobti RC, Singla N, Sundar S. Anti-66 kDa antileishmanial antibodies as specific immunodiagnostic probe for visceral leishmaniasis. *Indian J Med Res.* 99: 109-14, 1994. PMID: 8063345
447. Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, Mahapatra TM, Singh VP. Clinicoepidemiological study of drug resistance in Indian kala-azar. *BMJ.* 308: 307, 1994. PMID: 8124119
448. Singh VP, Sundar S, Kumar K, Shukla J, Dube B 1994. Plasma cell leukemia--report on two cases. *J Assoc Physicians India.* 42: 824-5, 1994. PMID: 7876056
449. Singh VP, Sundar S, Kumar K, Shukla J, Dube B. Down's syndrome with acute myeloid leukemia. *J Assoc Physicians India.* 42 :621, 1994. PMID: 7868556
450. Singh S, Sundar S. Toxicity of pentavalent antimony Letter. *J Assoc Physicians India.* 42: 755, 1994. PMID: 7741886
451. Singh VP, Sundar S, Kumar K, Shukla J, Dube B. "Prolymphocytoid" transformation of chronic lymphocytic leukemia. *J Assoc Physicians India.* 41: 312, 1993. PMID: 8300471
452. Singh VP, Sundar S, Kumar K, Dube B, Dube RK. Acquired pure red cell aplasia: is chloroquine a culprit? *J Assoc Physicians India.* 41: 607, 1993. PMID: 8307924
453. Singla N, Singh GS, Sundar S, Vinayak VK. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. *Trans R Soc Trop Med Hyg.* 87: 276-8, 1993. PMID: 8236390
454. Sundar S, Moorleedhur-Singh GS, Dube B, Singh VP, Kumar K. Danazol in Indian haemophiliacs. *J Assoc Physicians India.* 41: 23-5, 1993. PMID: 8340322
455. Sundar S, Moorleedursingh GS, Kumar K, Dube B, Singh VP. Danazol therapy in chronic idiopathic thrombocytopenic purpura. *J Assoc Physicians India.* 40: 350-1, 1992. PMID: 1484008
456. Gupta RK, Bhattacharya SK, Sundar S, Kumar K, Kachhawaha JS, Sen PC. A correlative study of serum zinc and in vivo cell mediated immune status in rheumatic heart disease. *Acta Cardiol.* 47: 297-304, 1992. PMID: 1523910
457. Sundar S, Singh VP. Chronic myeloid leukaemia with massive lymphadenopathy. *J Assoc Physicians India.* 40: 285, 1992. PMID: 1452552
458. Sundar S, Kumar K, Singh VP, Mahapatra TM. Diagnostic lag period in kala-azar: test for early diagnosis needed Letter. *J Assoc Physicians India.* 39: 651, 1991. PMID: 1814888
459. Bhattacharya SK, Gupta RK, Kumar K, Sundar S, Kachhawaha JS, Sen PC. Zinc in rheumatic heart disease--role in immunopathogenesis? *J Assoc Physicians India.* 39: 428, 1991. PMID: 1960175

460. Sundar S, Mall RK, Dube B, Singh VP. Antithrombin III in liver disorders. *J Assoc Physicians India.* 39: 522-4, 1991. PMID: 1800493
461. Sundar S, Rajan AG, Somani PN, Kumar K 1991. The effects of antihypertensive agents on the quality of life in Indian hypertensives. *Acta Cardiol.* 46: 227-35, 1991. PMID: 2048369
462. Singh V, Bhattacharya SK, Sundar S, Kachhawaha JS. Serum and urinary copper in acute hepatic encephalopathy. *J Assoc Physicians India.* 38: 467-9, 1990. PMID: 2292550
463. Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis (Letter). *Lancet.* 336: 1582-3, 1990. PMID: 1979393
464. Singh DS, Gupta SS, Gupta R, Gambhir IS, Sundar S, Agrawal AK. Bleeding from gastric ulcer in portal hypertension Letter. *J Assoc Physicians India.* 38:5 18-9, 1990. PMID: 2292570
465. Gupta SS, Gupta R, Gambhir IS, Sundar S, Agrawal AK, Singh DS. Inferior venacaval obstruction following burns (Letter). *J Assoc Physicians India.* 38: 243, 1990. PMID: 2391308
466. Singh SB, Singh VP, Gupta S, Gupta RM, Sundar S. Tropical myositis. A clinical immunological and histopathological study. *J Assoc Physicians India.* 37: 561-3, 1989. PMID: 2632556
467. Singh V, Bhattacharya SK, Sundar S, Kachhawaha JS. Zinc levels in the cerebrospinal fluid, serum & urine in acute hepatic encephalopathy. *Indian J Med Res.* 87: 594-9, 1988. PMID: 3240938
468. Sundar S. Prostacyclin in extracted plasma of essential hypertensives. *Acta Cardiol.* 42: 135-9, 1987. PMID: 3300116
469. Agarwal SK, Sundar S. Which regimen to be used in retreatment cases of pulmonary tuberculosis? (Letter) *J Assoc Physicians India.* 34: 227, 1986. PMID: 3733660
470. Singh DS, Sundar S and Tripathi KK. Tricyclic antidepressant therapy in duodenal ulcer. *J Indian Med Assoc.* 85: 265-7, 1987. PMID: 3450741
471. Bhattacharya SK, Sundar S. Unusual cases of herpes zoster involving cranial nerves (Letter). *J Assoc Physicians India.* 34: 161, 1984. PMID: 3711014
472. Agarwal SK, Sundar S. Empyema (Letter). *J Assoc Physicians India.* 33: 681-2, 1985. PMID: 4093377
473. Sundar S, Bhattacharya SK, Chowdhary R, Dube B. Polymphocytic leukaemia. *J Indian Med Assoc.* 83: 244-5, 1985. PMID: 3866798
474. Bhattacharya SK, Sundar S, Sabharwal NC. Massive splenomegaly (regressing with therapy) in amoebic liver abscess. *J Indian Med Assoc.* 83: 202-4, 1985. PMID: 2867115
475. Agarwal SK, Sundar S. Drip method in empyema thoracis (Letter). *J Assoc Physicians India.* 33: 250, 1985. PMID: 4044490
476. Agarwal K, Roy DC, Matah SC, Sundar S. Retreatment of pulmonary tuberculosis. *J Assoc Physicians India.* 33: 814-6, 1985. PMID: 3837007
477. Sundar S, Sachdev KK, Vaish SK, Bhattacharya SK, Singh VP, Agarwal SK. Potassium supplementation in essential hypertension--a double blind placebo controlled study. *J Assoc Physicians India.* 33: 776-7, 1985. PMID: 3915499
478. Agrawal NR, Singh V, Bhattacharya SK, Sundar S, Tiwari P. Prognostic significance of zinc in pregnancy with hepatitis. *Asia Oceania J Obstet Gynaecol.* 11: 589-91, 1985. PMID: 3833161
479. Pandey SP, Bhattacharya SK, Sundar S. Zinc in rheumatoid arthritis.

---

*Indian J Med Res.* 81: 618-20, 1985. PMID: 4054969

480. Agarwal SK, Roy DC, Sundar S, Matah SC. Short course intermittent chemotherapy in pulmonary tuberculosis. *J Assoc Physicians India.* 33: 281-2, 1985. PMID: 4030678
481. Singh DS, Seecatt JS, Sundar S, Rai AK, Dube RK, Gupta JP, Srivastava PK. Platelets in hepatic disorders. *J Assoc Physicians India.* 33: 453-5, 1985. PMID: 4055662
482. Sundar S, Kapil R, Dube B, Vaish SK. Antithrombin-III activity in ischaemic heart disease. *Indian Heart J.* 36: 46-9, 1984. PMID: 6423518
483. Sundar S, Sinha AK, Vaish SK. Blood carboxyhaemoglobin: a better index of smoking. *J Assoc Physicians India.* 32: 803-4, 1984. PMID: 6511771
484. Sundar S, Shyam B, Gulathi AK, Somani PN. Coxsackie--a viral carditis in eastern India. *J Assoc Physicians India.* 32: 501-3, 1984. PMID: 6096350
485. Sundar S, Singh VP, Burma DP, Vaish SK. Digoxin induced arrhythmias and electrolytes. *Indian Heart J.* 36: 104-6, 1984. PMID: 6724624
486. Sundar S, Agrawal SK, Singh VP, Bhattacharya SK, Udupa KN, Vaish SK. Role of yoga in management of essential hypertension. *Acta Cardiol.* 39: 203-8, 1984. PMID: 6331698
487. Sundar S. Is bradycardia dependent intermittent bundle branch block digoxin induced? (Letter) *J Assoc Physicians India.* 32: 762, 1984. PMID: 6511761
488. Sundar S, Avasthey P, Burma DP, Vaish SK. Intermittent right bundle branch block due to digoxin toxicity--a rare electrocardiographic manifestation. *Indian Heart J.* 35: 238-40, 1983. PMID: 6629406
489. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. *Acta Cardiol.* 38: 115-23, 1983. PMID: 6603084
490. Bhattacharya SK, Sundar S, Gupta PR, Singh TJ, Vaish SK. Scleredema – Some unusual features case report. *Indian J Derm Ven Lep.* 48: 365-369, 1982. PMID: 28193923
-